# EDGAR Filing Document

**Accession Number:** 0002007825
**File Stem:** 0001193125-26-134690
**Filing Date:** 2026-3
**Character Count:** 220548
**Document Hash:** 25faa9a81f07fb7eb1f33bf910194ffb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-134690.hdr.sgml**: 20260331

**ACCESSION NUMBER**: 0001193125-26-134690

**CONFORMED SUBMISSION TYPE**: 8-K/A

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20260213

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260331

**DATE AS OF CHANGE**: 20260331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Infleqtion, Inc.
- **CENTRAL INDEX KEY:** 0002007825
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42646
- **FILM NUMBER:** 26822423

**BUSINESS ADDRESS:**
- **STREET 1:** 1315 WEST CENTURY DRIVE
- **STREET 2:** SUITE 150
- **CITY:** LOUISVILLE
- **STATE:** CO
- **ZIP:** 80027
- **BUSINESS PHONE:** (303) 440-1284

**MAIL ADDRESS:**
- **STREET 1:** 1315 WEST CENTURY DRIVE
- **STREET 2:** SUITE 150
- **CITY:** LOUISVILLE
- **STATE:** CO
- **ZIP:** 80027

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Churchill Capital Corp X/Cayman
- **DATE OF NAME CHANGE:** 20240110

?xml version='1.0' encoding='ASCII'? 8-K/A

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K/A

#### (Amendment No. 1)

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): February 13, 2026

## INFLEQTION, INC.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-42646** | **86-1946291** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| |
|:---|
| **1315 West Century Drive, Suite 150** |
| **Louisville, CO 80027** |
| **(Address of principal executive offices, including zip code)** |

---

(303) 440-1284

#### (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol** | **Name of each exchange**<br> **on which registered** |
| Common Stock, par value $0.0001 per share | INFQ | The New York Stock Exchange |
| Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share | INFQ WS | The New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### EXPLANATORY NOTE
This Amendment No. 1 to the Current Report on Form 8-K/A is being filed with the Securities and Exchange Commission to amend the Current Report on Form 8-K filed by Infleqtion, Inc. (the "Company") on February 17, 2026 (the "Original Report").

The Company is filing this Amendment No. 1 to the Original Report to include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the audited financial statements of ColdQuanta, Inc. ("Legacy Infleqtion"), as of and for the years ended December 31, 2025 and 2024 as Exhibit 99.1; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Management's Discussion and Analysis of Financial Conditions and Results of Operations of Legacy Infleqtion as of and for the years ended December 31, 2025 and 2024 as Exhibit 99.2.

This Amendment No. 1 does not amend any other item of the Original Report or purport to provide an update or a discussion of any developments at the Company or its subsidiaries subsequent to the filing date of the Original Report. The Original Report remains unchanged. Capitalized terms used herein but not defined herein have the meanings given to such terms in the Original Report.

#### Item 2.02 Results of Operations and Financial Condition.
The audited financial statements of Legacy Infleqtion as of and for the years ended December 31, 2025 and 2024 are set forth in Exhibit 99.1 hereto and the management's discussion and analysis of financial condition and results of operations of Legacy Infleqtion as of and for the years ended December 31, 2025 and 2024 are set forth in Exhibit 99.2 hereto and each are incorporated herein by reference.

#### Item 9.01 Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired

The audited financial statements of Legacy Infleqtion as of and for the years ended December 31, 2025 and 2024 are set forth in Exhibit 99.1 hereto and are incorporated herein by reference.

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 99.1 | [Audited financial statements of Legacy Infleqtion as of and for the years ended December 31, 2025 and 2024.](d104197dex991.htm) |
| 99.2 | [Management's Discussion and Analysis of Financial Condition and Results of Operations of Legacy Infleqtion as of and for the years ended December 31, 2025 and 2024.](d104197dex992.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL). |

---

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **INFLEQTION, INC.** | **INFLEQTION, INC.** |
| Dated: March 31, 2026 |  |  |
|  | By: | /s/ Ilan Hart |
|  | Name: | Ilan Hart |
|  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1** 

**ColdQuanta, Inc. dba Infleqtion** 

**Consolidated Financial Statements** 

**For the Years Ended December 31, 2025 and 2024** 

**Table of Contents** 

---

| | |
|:---|:---|
|  | **Page(s)** |
|  Report of Independent Registered Public Accounting Firm | 2 |
|  Consolidated Balance Sheets | 3 |
|  Consolidated Statements of Operations and Comprehensive Loss | 4 |
|  Consolidated Statements of Changes in Convertible Redeemable Preferred Stock and Stockholders' Deficit | 5 |
|  Consolidated Statements of Cash Flows | 6 |
|  Notes to Consolidated Financial Statements | 7-32 |

---

------

**Report of Independent Registered Public Accounting Firm** 

To the Stockholders and Board of Directors

ColdQuanta, Inc. dba Infleqtion:

*Opinion on the Consolidated Financial Statements* 

We have audited the accompanying consolidated balance sheets of ColdQuanta, Inc. dba Infleqtion and subsidiaries (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, changes in convertible redeemable preferred stock and stockholders' deficit, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years then ended, in conformity with U.S. generally accepted accounting principles.

*Basis for Opinion* 

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

![LOGO](g104197g0330004059530.jpg)

We have served as the Company's auditor since 2022.

Denver, Colorado

March 31, 2026

------

**ColdQuanta, Inc. dba Infleqtion** 

**Consolidated Balance Sheets** 

*(in thousands, except share amounts)* 

---

| | | |
|:---|:---|:---|
|  | **As of December 31,** | **As of December 31,** |
|  | **2025** | **2024** |
|  **ASSETS** |  |  |
|  **CURRENT ASSETS:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cash and cash equivalents | $11694 | $47942 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Available-for-sale securities, current | 34318 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts receivable | 9543 | 4033 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unbilled receivables | 4734 | 3558 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inventories | 4299 | 2223 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid expenses and other current assets | 10036 | 3195 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total current assets** | **74624** | **60951** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Property and equipment, net | 8674 | 10015 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Operating lease right-of-use assets | 4923 | 5400 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Available-for-sale securities, non-current | 17157 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Goodwill | 9315 | 9315 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other assets | 620 | 637 |
|  **TOTAL ASSETS** | $**115313** | $**86318** |
|  **LIABILITIES, CONVERTIBLE REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT** |  |  |
|  **CURRENT LIABILITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts payable | $5644 | $1361 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accrued liabilities | 8610 | 9278 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contract liabilities | 6871 | 3402 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Current portion of operating lease right-of-use liabilities | 1076 | 1324 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred consideration payable, current | 471 | 1362 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total current liabilities** | **22672** | **16727** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Operating lease liabilities, net of current portion | 4074 | 4774 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred consideration payable |  | 408 |
|  **TOTAL LIABILITIES** | **26746** | **21909** |
|  **Convertible Redeemable Preferred Stock:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Series Seed convertible redeemable preferred stock, $0.0001 par value per share | 6526 | 6526 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Series Seed II convertible redeemable preferred stock; $0.0001 par value per share | 10411 | 10411 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Series A convertible redeemable preferred stock, $0.0001 par value per share | 36658 | 36658 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Series B convertible redeemable preferred stock; $0.0001 par value per share | 112145 | 112145 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Series B-1 convertible redeemable preferred stock; $0.0001 par value per share | 32990 | 32990 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Series C convertible redeemable preferred stock ; $0.0001 par value per share | 71733 | 22503 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Series C-1 convertible redeemable preferred stock ; $0.0001 par value per share | 26351 | 26351 |
|  **Total Convertible Redeemable Preferred Stock** | **296814** | **247584** |
|  Commitments and contingencies (refer to note 12) |  |  |
|  **Stockholders' Deficit:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common stock: $0.0001 par value per share; 573,000,000 shares authorized as of December 31, 2025 and 2024; 50,227,011 and 45,512,715 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 5 | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Additional paid-in capital | 21928 | 15751 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accumulated deficit | (231086) | (199291) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accumulated other comprehensive income | 906 | 360 |
|  **Total Stockholders' Deficit** | **(208247)** | **(183175)** |
|  **Total Liabilities, Convertible Redeemable Preferred Stock and Stockholders' Deficit** | $**115313** | $**86318** |

---

*The accompanying notes are an integral part of these consolidated financial statements* 

------

**ColdQuanta, Inc. dba Infleqtion** 

**Consolidated Statements of Operations and Comprehensive Loss** 

*(in thousands, except share and per share amounts)* 

---

| | | |
|:---|:---|:---|
|  | **For the period ended December 31,** | **For the period ended December 31,** |
|  | **2025** | **2024** |
|  **Revenue** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Product revenue | $19614 | $22325 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Service revenue | 12850 | 6511 |
|  **Total revenue** | **32464** | **28836** |
|  **Cost of revenue** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cost of products | 13558 | 17571 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cost of services | 7093 | 2201 |
|  **Total cost of revenue** | **20651** | **19772** |
|  **Gross profit** | **11813** | **9064** |
|  Research and development | 24089 | 22303 |
|  Selling, general and administrative | 25343 | 27287 |
|  Impairment of assets and goodwill |  | 13539 |
|  Grant income | (2333) | (1057) |
|  **Loss from operations** | **(35286)** | **(53008)** |
|  Other income (expense): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest income | 2502 | 1154 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in fair value of SAFE liabilities |  | (2271) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in fair value of contingent consideration |  | 380 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other, net | 989 | (21) |
|  **Total other (expense) income, net** | **3491** | **(758)** |
|  **Loss before income taxes** | **(31795)** | **(53766)** |
|  Income tax expense (benefit) |  | (2) |
|  **Net loss** | $**(31795)** | $**(53764)** |
|  Other comprehensive income: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unrealized income on available-for-sale securities | 140 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Foreign currency translation adjustment | 406 | 474 |
|  **Total other comprehensive income** | **546** | 474 |
|  **Comprehensive loss** | $**(31249)** | $**(53290)** |
|  Net loss per share attributable to common stockholders - basic and diluted | $(0.69) | $(1.35) |
|  Weighted average shares used in computing net loss per share attributable to common stockholders – basic and diluted | 46185671 | 39808027 |

---

*The accompanying notes are an integral part of these consolidated financial statements* 

------

**ColdQuanta, Inc. dba Infleqtion** 

**Consolidated Statements of Changes in Convertible Redeemable Preferred Stock and Stockholders' Deficit** 

*(in thousands, except share amounts)* 

---

| | | | | | | | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Convertible Redeemable Preferred Stock** | **Convertible Redeemable Preferred Stock** | **Convertible Redeemable Preferred Stock** | **Convertible Redeemable Preferred Stock** | **Convertible Redeemable Preferred Stock** | **Convertible Redeemable Preferred Stock** | **Convertible Redeemable Preferred Stock** | **Convertible Redeemable Preferred Stock** | **Convertible Redeemable Preferred Stock** | **Convertible Redeemable Preferred Stock** | **Convertible Redeemable Preferred Stock** | **Convertible Redeemable Preferred Stock** | **Convertible Redeemable Preferred Stock** | **Stockholders' Deficit** | **Stockholders' Deficit** | **Stockholders' Deficit** | **Stockholders' Deficit** | **Stockholders' Deficit** | **Stockholders' Deficit** | **Stockholders' Deficit** |
|  | **Series Seed** | **Series Seed** | **Series Seed II** | **Series Seed II** | **Series A** | **Series A** | **Series B** | **Series B** | **Series B-1** | **Series B-1** | **Series C** | **Series C** | **Series C-1** | **Series C-1** | **Common Stock** | **Common Stock** | **Additional<br>Paid-in<br>Capital** | **Accumulated<br>Deficit** | **Accumulated**<br>**Other<br>Comprehensive<br>Income (Loss)** | **Total<br>Stockholders'<br>Deficit** |
|  | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | | | | |
|  **Balances as of December 31, 2023** | 24871033 | $6526 | 27499984 | $10411 | 101515976 | $36658 | 107814417 | $107395 | 32419574 | $32990 |  |  |  |  | 35831766 | $4 | $10468 | $(145527) | $(114) | $(135169) |
|  Convertible redeemable preferred stock issue, net |  |  |  |  |  |  | 6141902 | 4750 |  |  | 20508938 | 22503 |  |  |  |  |  |  |  |  |
|  SAFE notes conversion |  |  |  |  |  |  |  |  |  |  |  |  | 22869771 | 26351 |  |  |  |  |  |  |
|  Common stock issued in acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4457536 |  | 436 |  |  | 436 |
|  Issuance of contingent consideration shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50 |  |  | 50 |
|  Net loss |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (53764) |  | (53764) |
|  Stock-based compensation expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3741 |  |  | 3741 |
|  Stock options exercised |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5223413 | 1 | 1056 |  |  | 1057 |
|  Other comprehensive income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 474 | 474 |
|  **Balances as of December 31, 2024** | 24871033 | $6526 | 27499984 | $10411 | 101515976 | $36658 | 113956319 | $112145 | 32419574 | $32990 | 20508938 | $22503 | 22869771 | $26351 | 45512715 | $5 | $15751 | $(199291) | $360 | $(183175) |
|  Convertible redeemable preferred stock issue, net |  |  |  |  |  |  |  |  |  |  | 39891014 | 49230 |  |  |  |  |  |  |  |  |
|  Settlement of contingent liability with common stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2163 |  |  | 2163 |
|  Net loss |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (31795) |  | (31795) |
|  Stock-based compensation expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3056 |  |  | 3056 |
|  Stock options exercised |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4714296 |  | 958 |  |  | 958 |
|  Other comprehensive income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 546 | 546 |
|  **Balances as of December 31, 2025** | 24871033 | $6526 | 27499984 | $10411 | 101515976 | $36658 | 113956319 | $112145 | 32419574 | $32990 | 60399952 | $71733 | 22869771 | $26351 | 50227011 | $5 | $21928 | $(231086) | $906 | $(208247) |

---

*The accompanying notes are an integral part of these consolidated financial statements* 

------

**ColdQuanta, Inc. dba Infleqtion** 

**Consolidated Statements of Cash Flows** 

*(in thousands)* 

---

| | | |
|:---|:---|:---|
|  | **Years Ended December 31,** | **Years Ended December 31,** |
|  | **2025** | **2024** |
|  **Cash flows from operating activities** |  |  |
|  Net loss | $(31795) | $(53764) |
|  Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depreciation and amortization expense | 3692 | 2616 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock-based compensation expense | 3056 | 3741 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in fair value of contingent obligation | 3992 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-cash transfer of property, plant and equipment |  | 686 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in fair value of SAFE notes |  | 2271 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in fair value of contingent consideration |  | (380) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impairment of assets and goodwill |  | 13539 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other non-cash operating adjustments | (328) | 281 |
|  Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts receivable | (5379) | (1981) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inventories | (2076) | (944) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unbilled receivables | (1176) | (2254) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid expenses and other current assets | (411) | 582 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other assets | (11) | (225) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts payable | 3786 | (987) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accrued liabilities | (493) | 3563 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contract liabilities | 3469 | 851 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Operating lease right-of-use assets | 710 | (2511) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Operating lease right-of-use liabilities | (1181) | 2449 |
|  Net cash used in operating activities | (24145) | (32467) |
|  **Cash flows from investing activities** |  |  |
|  Purchases of available-for-sale securities | (56759) |  |
|  Redemptions of available-for-sale securities | 5600 | 12660 |
|  Purchases of property and equipment | (2372) | (2858) |
|  Morton acquisition, net of cash acquired |  | (3041) |
|  SiNoptiq asset acquisition |  | (2655) |
|  Net cash provided by (used in) investing activities | (53531) | 4106 |
|  **Cash flows from financing activities** |  |  |
|  Proceeds from issuance of Series C convertible redeemable preferred stock | 49225 | 25153 |
|  Proceeds from issuance of SAFE Notes, net of issuance costs |  | 22655 |
|  Proceeds from stock options exercised | 958 | 1057 |
|  Payment of Series C convertible redeemable preferred stock accrued issuance costs | (2800) |  |
|  Payment of deferred offering costs | (5206) |  |
|  Payment of deferred cash consideration | (1425) | (475) |
|  Net cash provided by financing activities | 40752 | 48390 |
|  Foreign currency translation | 676 | 451 |
|  Net increase (decrease) in cash and cash equivalents and restricted cash | $(36248) | $20480 |
|  Cash, cash equivalents and restricted cash at beginning of period | $48142 | $27662 |
|  **Cash, cash equivalents and restricted cash at end of period** | $**11894** | $**48142** |
|  **Supplemental non-cash disclosure of cash flow information** |  |  |
|  Acquisition of assets through issuance of equity | $— | $5236 |
|  Acquisition of assets through deferred payment arrangements | $— | $1964 |
|  Series C convertible redeemable preferred stock unpaid issuance costs | $— | $2650 |
|  Unpaid deferred offering costs | $1178 | $— |
|  Unrealized gains or losses on available-for-sale securities | $140 | $— |
|  Settlement of contingent liability with common stock | $2163 | $— |

---

*The accompanying notes are an integral part of these consolidated financial statement* 

------

**ColdQuanta, Inc. dba Infleqtion** 

**Notes to the Consolidated Financial Statements** 

**1. Summary of Operations and Significant Accounting Policies** 

***Nature of Operations***

ColdQuanta, Inc. dba Infleqtion ("ColdQuanta") together with its wholly owned subsidiaries, (collectively the "Company") develops and commercializes quantum technology products as part of a full-stack platform, which currently includes offerings such as: quantum sensing, quantum computing and software. The Company's quantum-enabled solutions are focused on addressing pressing challenges, with technologies actively deployed across a number of sectors today, including defense and security, artificial intelligence ("AI"), energy optimization, space and frontier, materials discovery and cybersecurity. The Company's quantum sensors and computers are supported by the Company's proprietary software, Superstaq, which serves as a control panel for future hybrid quantum-classical workflows. In addition, the Company has developed contextual machine learning software, based on quantum physics principles, that increases AI performance today on classical graphics processing units. To serve the market as a multi-platform quantum technology company, the Company engages in multiple research and development areas. The Company is engaged in research and development of neutral atom quantum computers that may have uses in military, drug design, investment strategies, encryption-cracking and complex scheduling problems. The Company is also a developer and supplier of Bose-Einstein condensates and cold atom devices, instruments and systems and quantum software applications and platforms. The Company's customers are primarily government agencies of the United States ("U.S."), such as the U.S. Department of Defense, the Defense Advanced Research Projects Agency and similar government agencies in the United Kingdom ("U.K.") who contract with the Company for research and development services and the production of technical devices. The Company also sells critical supply chain quantum devices and machines to commercial customers.

ColdQuanta was formed as a Colorado corporation on February 7, 2007 and subsequently converted to a Delaware corporation on June 29, 2018. The Company is located and headquartered in Colorado with operations in; Illinois; Texas; Wisconsin; Melbourne, Australia and Oxford, U.K.

***Churchill Capital Corp X Business Combination Agreement***

On February 13, 2026, pursuant to the definitive agreement and plan of merger and reorganization (the "Merger Agreement"), dated September 8, 2025, with Churchill Capital Corp X, a publicly traded special purpose acquisition company ("CCX"), AH Merger Sub I, Inc., a direct, wholly owned subsidiary of CCX, was merged with and into the Company, with the Company continuing as the surviving corporation. Immediately thereafter, such surviving corporation was merged with and into AH Merger Sub II, LLC ("Merger Sub II"), another direct, wholly owned subsidiary of CCX, with Merger Sub II (renamed as "Infleqtion Quantum, LLC") continuing as the surviving entity and as a wholly owned subsidiary of CCX (collectively, the "Business Combination"). In connection with the closing of the Business Combination ("the Closing"), CCX changed its name to Infleqtion, Inc.

Further, immediately prior to completing the Business Combination, each issued and outstanding share of ColdQuanta common stock, preferred stock and restricted stock was automatically surrendered and exchanged for the right to receive shares of CCX common stock, par value $0.0001 per share based on a defined exchange ratio of 0.3470312, representing Infleqtion, Inc. Common Stock after the Closing.

Immediately following the Closing, there were 216,471,927 shares of Infleqtion, Inc. Common Stock issued and outstanding. Of those shares, 151,804,988 shares were issued to holders of ColdQuanta securities in respect of such securities, representing approximately 70.1% of the voting rights in Infleqtion, Inc. following the Closing.

As of December 31, 2025, the Company has incurred $6.4 million of direct and incremental costs in connection with the Business Combination which are recorded in prepaid expenses and other current assets in the consolidated balance sheets. These deferred offering costs will be recognized in the statement of equity as a reduction of additional paid-in capital upon consummation of the Business Combination.

***Basis of Presentation***

The accompanying consolidated financial statements include the financial results of ColdQuanta and its wholly owned subsidiaries and have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). All intercompany balances and transactions have been eliminated in consolidation.

Certain prior-year amounts have been reclassified for presentation purposes to conform to the current-year presentation.

***Emerging Growth Company***

Upon completion of the Business Combination, the Company expects to operate as an Emerging Growth Company ("EGC") under the Securities Act, as modified by the Jumpstart Our Business Startups Act ("JOBS Act") and may take advantage of certain exemptions from reporting and disclosure requirements that apply to other public companies that are not EGCs.

Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with

------

the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard, until such time the Company is no longer considered to be an emerging growth company. At times, the Company may elect to early adopt a new or amended standard.

***Use of Estimates***

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in these consolidated financial statements and the accompanying notes.

Significant estimates and judgments are inherent in the analysis and measurement of items including, but not limited to, the selection of the method to measure progress in the satisfaction of performance obligations in revenue arrangements recognized over time and the related estimate of total expected costs for the revenue arrangement, the useful lives of long-lived assets, the fair value of stock-based awards, the fair value of assets and liabilities acquired in business combinations, the fair value of contingent consideration, the fair value of contingent obligation and the fair value of assets and reporting units associated with impairment losses. Management bases its estimates and assumptions on current facts, historical experience, expectations, forecasts, trends and various other factors that are believed to be reasonable under the circumstances. Due to the inherent uncertainty involved in making estimates, actual results could differ materially from such estimates and assumptions.

***Concentrations of Credit Risk and other Risks and Uncertainties***

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents, available-for-sale securities and accounts receivable. The Company's cash and cash equivalents are deposited at high-credit-quality financial institutions. The Company's deposit balances at these institutions routinely exceed federally insured limits. The Company has not experienced any credit losses relating to its cash and cash equivalents and does not believe there is exposure to any significant credit risk on such accounts. See the section below for further information on available-for-sale securities.

The majority of the Company's accounts receivable is derived from governmental institutions and commercial customers primarily located in the U.S., U.K., Australia and Japan. At December 31, 2025, one customer represented 78% of total accounts receivable. At December 31, 2024, two customers represented 57% and 25% of total accounts receivable. There have been no credit losses since the Company's inception.

Significant customers are those that represent more than 10% of the Company's total revenue. During the year ended December 31, 2025, two customers represented 60% and 12% of total revenue. During the year ended December 31, 2024, three customers represented 36%, 32% and 12% of total revenue.

A significant portion of the Company's resources are engaged in supplying services and technological equipment to the U.S. and U.K. governments and can be subject to certain business risks unique to being a government contractor. Sales to government entities may be affected by changes in procurement policies, turnover of key personnel, budget considerations, political developments abroad and other factors. In addition, the Company is subject to periodic compliance audits by the U.S. and U.K. governments.

The Company is also subject to the risks inherent in any technological business model, including the development of competing products and technologies and the related risk of obsolescence. The Company's current focus is on research and development of quantum technology. However, the quantum technology industry is still in its early stage and the Company may not be successful in all of its research and development.

***Accounting Pronouncements Recently Issued or Adopted***

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2023-09, *Improvements to Income Tax Disclosures*, which requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. This ASU is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This ASU is effective for the Company for annual periods beginning after December 15, 2025, with the option to apply the ASU retrospectively. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company early adopted this ASU on a prospective basis as of December 31, 2025 and determined that the adoption of this ASU will not have a material impact on the consolidated financial statements.

In November 2024, the FASB issued ASU No. 2024-03, *Disaggregation of Income Statement Expenses*. This ASU requires additional disclosure of the nature of expenses included in the income statement. This ASU is effective for the Company for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with the option to apply the ASU retrospectively. Early adoption is permitted. The Company is currently evaluating the extent of the impact of this ASU on the disclosures in the Company's consolidated financial statements.

In May 2025, the FASB issued ASU 2025-03, *Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity*, which amends guidance in the FASB Accounting Standards Codification (ASC) 805, *Business Combinations* and ASC 810, *Consolidation*, related to determining the accounting acquirer in a business combination when the legal acquiree is a variable interest entity ("VIE"). The updates remove the previous requirement that the primary beneficiary of a VIE is automatically the accounting

------

acquirer. Instead, entities must apply the general factors in ASC 805-10-55-12 through 55-15 when the transaction is primarily impacted by exchanging equity interests. This change allows certain transactions, including those involving VIEs, to be accounted for as reverse acquisitions when appropriate. This ASU is effective for the Company for annual periods beginning after December 15, 2026, and interim periods within those annual periods. Early adoption is permitted in an interim or annual reporting period in which financial statements have not yet been issued (or made available for issuance). If an entity early adopts in an interim reporting period, it can adopt as of the beginning of that interim reporting period or the beginning of the annual reporting period that includes that interim reporting period. The Company early adopted this ASU effective January 1, 2025. The adoption of this ASU did not have a material impact on the consolidated financial statements.

In November 2025, the FASB issued ASU 2025-06*, Targeted Improvements to the Accounting for Internal-Use Software,* which modernizes accounting for internal-use software development costs, aligning with evolving technology practices. This ASU is effective for the Company for annual periods beginning after December 15, 2027, and interim periods within those annual periods. Early adoption is permitted in an interim or annual reporting period in which financial statements have not yet been issued (or made available for issuance). If an entity early adopts in an interim reporting period, it must adopt as of the beginning of the annual reporting period that includes that interim reporting period. The Company is currently evaluating the extent of the impact of this ASU on the Company's consolidated financial statements.

In December 2025, the FASB issued ASU 2025-10, *Accounting for Government Grants Received by Business Entities*, ("ASU 2025-10") which establishes guidance on the recognition, measurement and presentation of a government grant received by a business entity. GAAP did not provide such guidance, and many business entities have been analogizing to International Accounting Standard ("IAS") 20 or other guidance when accounting for government grants. The ASU incorporates elements of IAS 20 into GAAP, modifying certain aspects of that standard's scope, recognition threshold and other implementation guidance. This ASU is effective for the Company for annual periods beginning after December 15, 2029, and interim periods within those annual periods. Early adoption is permitted in an interim or annual reporting period in which financial statements have not yet been issued (or made available for issuance). If an entity early adopts in an interim reporting period, it must adopt as of the beginning of the annual reporting period that includes that interim reporting period. The Company is currently evaluating the extent of the impact of this ASU on the Company's consolidated financial statements.

***Cash and Cash Equivalents and Restricted Cash***

Cash and cash equivalents include cash in banks, checking deposits and money market funds. The Company considers all highly liquid investments purchased with an original maturity at the date of acquisition of three months or less to be cash equivalents. Cash balances, which may be in excess of federally insured limits, are deposited in financial institutions.

At December 31, 2025 and 2024, the Company's restricted cash totaled $0.2 million related to cash deposits for an office building lease. The restricted cash is classified as other long-term assets on the Company's consolidated balance sheets; however, it is included in the reconciliation of cash, cash equivalents and restricted cash for purposes of the consolidated statements of cash flows.

***Available-for-sale securities***

Under the Company's securities policy, available-for-sale securities may consist of investment grade commercial paper, corporate bonds, federal agency bonds, government bonds and other bonds issued in the U.S. (and denominated in the U.S. dollar) by foreign entities. Current available-for-sale securities are those with maturities of greater than three months, but less than one year. Noncurrent available-for-sale securities hold maturities greater than one year. The Company evaluates the classification of its securities at the time of purchase and re-evaluates such determination at each balance sheet date, which includes an assessment of the intent to hold the available-for-sale securities. The Company's securities policy sets minimum credit quality criteria and maximum maturity limits on the securities it holds to provide for preservation of capital, liquidity and a reasonable rate of return. The Company classifies its securities as available-for-sale.

Available-for-sale securities are recorded at fair value. Unrealized holding gains and losses on available-for-sale securities (except for credit losses) are excluded from net loss and are reported as a separate component of accumulated other comprehensive (loss) income until realized. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, the net amount of which, along with interest and realized gains and losses are included in interest income in the consolidated statements of operations. Realized gains are derived using the specific identification method for determining the cost of the securities sold. The Company evaluates whether a credit loss exists, and in the event a credit loss does exist, the credit loss is recognized in the consolidated statements of operations based on the amount that the fair value is less than the amortized cost.

***Accounts Receivable***

Accounts receivable primarily consist of amounts due from customers for which the Company has an unconditional right to receive payment for delivery of products and the performance of services. The Company's customers primarily consist of the U.S. federal government and its agencies, and universities. Amounts are generally due 30 days from the invoice date and do not bear interest.

On a periodic basis, management evaluates its accounts receivable to determine whether to provide an allowance for credit losses. Management considers relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of receivables. There were no significant changes in the Company's customer credit risk profile, economic conditions or methodology used to estimate expected credit losses during the periods presented, and the Company did not record any write-offs of trade receivables.

------

The Company did not have an allowance for credit losses as of December 31, 2025 or 2024.

***Inventories***

Inventories are stated at the lower of cost or net realizable value under the first-in-first-out (FIFO) assumption. Cost is determined using the weighted-average cost method. Costs include direct materials, direct labor and indirect facilities overhead costs that are allocated to inventory based on the portion of the Company's facilities used in manufacturing. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolescence or impaired inventory and are charged to cost of revenue. During the years ended December 31, 2025 and 2024, excess and obsolescence charges were $700 thousand and $48 thousand, respectively.

***Property and Equipment, Net***

Property and equipment, net is stated at cost less accumulated depreciation and amortization. Expenditures on improvements are capitalized, while expenditures on routine maintenance and repairs are expensed as incurred. Depreciation and amortization expense is calculated using the straight-line method over the estimated useful lives of the assets, as listed below:

---

| | |
|:---|:---|
| **Assets** | **Years** |
| Computers and equipment | 3-5 |
| Quantum computer | 3 |
| Leasehold improvements | Shorter of the useful life or the remaining lease term |
| Furniture and fixtures | 3 |
| Software and website | 1 |

---

***Leases***

The Company determines if an arrangement is or contains a lease at inception and classifies the lease as an operating or finance lease at the commencement date. An arrangement is or contains a lease where the Company has a right to control an identified asset. For leases with an initial term of greater than twelve months, the Company recognizes a right-of-use asset and a lease liability as of the lease commencement date. Right-of-use assets represent the Company's right to use the underlying assets for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease.

Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. Right-of-use assets are recognized as the initial measurement of the lease liabilities, plus any initial direct costs, any prepaid lease payments and less incentives received, if any.

The interest rate used to determine the present value of the future lease payments is the Company's incremental borrowing rate, because the implicit rates in the Company's leases are not readily determinable. The Company's incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments and in economic environments where the leased asset is located.

The Company recognizes lease expense for its operating leases on a straight-line basis over the lease term. Lease expense for finance leases is generally front-loaded as the finance lease right-of-use asset is depreciated on a straight-line basis, but interest expense on the liability is recognized utilizing the effective interest rate method that results in more expense during the early years of the lease. Accordingly, costs for finance leases are disaggregated and recognized as both an operating expense (for the amortization of the right-of-use asset) and interest expense (for interest on the lease liability).

The Company's operating and finance lease terms may include renewal or early termination options. The Company only includes renewal or termination options in the lease term when the options are reasonably certain of exercise. The assessment of whether such options are reasonably certain of exercise is based on facts and circumstances at lease commencement, including contract-based, asset-based and entity-based factors.

***Goodwill***

Goodwill is measured as the excess of the purchase price over the fair value of the assets acquired and liabilities assumed in a business combination. The Company tests goodwill for impairment on an annual basis, which is determined to be the first day of the fourth quarter, and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company performs impairment tests of goodwill at its reporting unit level, which is one level below its operating segments. The Company may elect to perform a qualitative assessment of goodwill in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount which would require a quantitative test.

If a quantitative test is required, the Company compares the fair value of the reporting unit to its carrying value, including goodwill. If the fair value of the reporting unit is lower than its carrying amount, goodwill is written down for the amount by which the carrying amount exceeds the fair value.

------

The fair value of the reporting unit is calculated using a market-based approach. This approach incorporates observable market data, including comparable company trading multiples, recent market transactions and other relevant valuation metrics. Key assumptions used in the market-based valuation include selection of appropriate publicly-traded peer companies with similar operational and financial characteristics, application of relevant valuation multiples derived from market data and adjustments for differences in size, growth prospects and risk profiles between the Company and its peers.

No impairment loss was recognized for the year ended December 31, 2025. A goodwill impairment loss of $1.5 million was recognized for the year ended December 31, 2024 related to the Company's acquisition of Morton Photonics Incorporated and Morton Hybrid Lasers LLC (collectively, "Morton"). Additional information is provided in Note 3—*Business Combination* and Note 5 – *Goodwill*.

***Intangible Assets, Net***

Intangible assets acquired in a business combination or in an asset acquisition that qualify for separate recognition are recognized at their fair value and amortized on a straight-line basis over their estimated useful lives or over the period the economic benefits of the asset are consumed. Residual values and useful lives are reviewed at each reporting date. Intangible assets consist of customer relationships, tradenames, software and order backlog.

***Business Combinations & Asset Acquisitions***

Upon obtaining control of another entity (even if less than 100% ownership is acquired), the Company first evaluates the transaction using the screen test to determine if the transaction constitutes the acquisition of a business in accordance with ASC 805, *Business Combinations* (ASC 805). The Company evaluates the net assets acquired to determine whether substantially all the fair value of the acquired assets is concentrated in a single identifiable asset or a group of similar identifiable assets. If substantially all the fair value of the assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets, the transaction does not meet the definition of a business combination and is accounted for as an asset acquisition. In an asset acquisition, the Company allocates the cost of the acquisition to the assets and liabilities acquired at their relative fair values. Direct acquisition-related costs (e.g., transaction costs) are included in the cost of the acquired assets.

If the fair value of the acquired assets is not concentrated in a single identifiable asset or group of similar identifiable assets, the Company then evaluates whether the net assets acquired meet the definition of a business in ASC 805. If the net assets acquired meet the definition of a business the transaction qualifies as a business combination and is accounted for by applying the acquisition method of accounting. Under the acquisition method the Company recognizes and measures the assets acquired and liabilities assumed in a business combination at their acquisition date fair values. Goodwill as of the acquisition date represents the excess of the purchase price over the fair value of the assets acquired net of liabilities assumed. The purchase consideration is determined based on the fair value of the assets transferred to the seller net of any liabilities assumed by the Company, after considering any transactions that are separate from the business combination. Subsequent adjustments may be recorded to the assets acquired and liabilities assumed, with a corresponding adjustment to goodwill, during the measurement period, which may be up to one year from the acquisition date, if the adjustments relate to events and circumstances that existed at the acquisition date. Transaction costs and costs to restructure the acquired company are expensed as incurred. The Company measures contingent consideration arrangements at fair value at each reporting period, with changes in fair value recognized in the consolidated statements of operations. Changes in the fair value of contingent consideration can result from changes in the likelihood of the contingency becoming more or less probable over time, as well as changes in the fair value of equity-based contingent consideration. The Company includes the results of all acquisitions in the consolidated financial statements from the date of acquisition.

***Warranty Liability***

The Company records warranty liabilities for the estimated costs of fulfilling its obligations under its product warranties at the time of sale. Warranty liabilities are included in accrued liabilities on the consolidated balance sheets. The Company generally issues one-year product warranties guaranteeing the product's intended functionality but may negotiate specific terms with certain customers. Liability under product warranties is estimated based on management's review of outstanding warranties, prior experience and specific customer circumstances. If actual results differ from estimates, the Company revises its estimated warranty liability. Warranty liabilities did not have a material impact on any period presented.

***Convertible Redeemable Preferred Stock***

The Company accounts for its preferred stock subject to possible redemption in accordance with the guidance in ASC 480, *Distinguishing Liabilities from Equity*. As all series of the Company's preferred stock are contingently redeemable upon the occurrence of events not solely within the Company's control, the preferred stock is presented as mezzanine equity, separate from the stockholders' deficit section of the consolidated balance sheet. The preferred stock is initially recorded at the fair value determined on the issuance date. Adjustments to the fair value of the preferred stock to the current market value are not made each period. Rather, the Company assesses whether the preferred stock has become redeemable or the probability that the preferred stock will become redeemable in determining whether to record subsequent measurement adjustments. Refer to Note 13 – *Convertible Redeemable Preferred Stock* for additional information.

***Revenue Recognition***

The Company primarily generates revenue from customers under governmental contracts and commercial contracts. Governmental revenue includes revenue recognized primarily from contracts with the U.S., U.K. and Australian governments. Commercial revenue includes revenue recognized primarily from contracts with research institutes and private companies located predominantly in the U.S. and U.K. Refer to Note 2 – *Revenue Recognition* for the Company's total revenue, as presented on the consolidated statement of operations and comprehensive loss, disaggregated by the geographic locations of the Company's customers and the percentage of total revenue derived from governmental customers.

------

The Company's government contracts are primarily related to research and development projects or the development of a product to agreed-upon specifications. Government contracts are typically either report-based research in which various activities are significantly integrated into the final report that is provided, or contracts are prototype- or product-based development in which the Company provides a significant service of integrating development activities throughout the term of the contract into the final prototype or product.

In certain instances, government contracts may contain multiple performance obligations where the Company delivers multiple final reports or multiple products across one or more phases in which the customer can benefit from the standalone good or service and each good or service is separately identifiable from other goods and services provided by the Company. Generally, the Company recognizes revenue over time as control of the goods or services is transferred to the customer. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided.

The Company generally uses an input method to measure progress toward completion for performance obligations satisfied over time, based on costs incurred relative to total estimated costs (cost-to-cost), as this method best depicts the transfer of control to the customer. The costs incurred are predominantly related to labor and materials, incurrence of which is indicative of progress and transfer of value to the customer. Under this method, revenue is recognized based on the proportion of costs incurred to date relative to total estimated costs, which includes an estimate of the total expected margin for fixed-price arrangements, where the transaction price is fixed. Accounting for long-term contracts requires significant judgment and estimation, which could be considerably different if the underlying circumstances were to change. When adjustments to estimated contract revenue or costs are required, changes from prior estimates are recognized on a cumulative catch-up basis in the period of change.

The Company's government contracts may include fixed and/or variable consideration. The resulting consideration is contracted either as a firm fixed price (which typically includes variable consideration contingent upon customer acceptance) or a cost-plus fixed fee arrangement (which includes fixed and variable consideration). Under a cost-plus fixed fee arrangement, the amount of variable consideration consists of direct and indirect costs plus a fixed fee.

The Company exercises judgment when estimating variable consideration to determine whether the most likely amount or expected value method should be used. Estimation of costs is based on historical knowledge and engineering expertise of tasks and components required to complete the project. A provisional rate, which is used as an initial estimate of indirect costs, is established through agreement with the government for all government contracts. Variable consideration is included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur.

Contracts with commercial customers generally contain separate performance obligations, as each individual product can be transferred independently of each other to the customer. Revenues under commercial contracts are generally recognized at a point in time when the Company satisfies its performance obligations and control of the goods or services transfers to the customer. Control typically transfers to the customer when the goods are shipped but can also transfer when the customer receives and accepts the goods, based on the terms of the contract. The transaction price for revenues under commercial contracts is fixed and stated in the contract with the customer. There are no forms of variable consideration or discounts offered for early payment in commercial contracts. The Company's commercial contracts typically include a standard one-year warranty period. These assurance-type warranties do not represent separate performance obligations because the warranties are only for the products to comply with agreed-upon specifications, and they do not provide the Company's customers with any additional distinct services. The Company has elected the practical expedient, enabling it to recognize shipping and handling costs performed after a customer obtains control of the good as fulfillment of the original performance obligation, rather than as a separate performance obligation, and includes such costs as a component of the transaction price.

The Company also has commercial service contracts that are primarily related to quantum software research and development projects. These contracts typically have a single performance obligation. The Company recognizes revenue over time as control of the goods or services is transferred to the customer. In these instances, the contracts have provisions that are deemed to transfer control to the customer over time. Similar to government service contracts, the Company generally uses an input measure of progress for its contracts based on costs incurred.

The transaction price for both government and commercial contracts typically does not include a significant financing component. For all contracts with customers, the Company has elected to exclude sales taxes from the transaction price.

The Company's contracts may be subsequently modified to include changes in specifications, requirements or price, which may create new or change existing enforceable rights and obligations. Depending on the nature of the modification, the Company considers whether to account for the modification as an adjustment to the existing contract or as a separate contract. Generally, modifications to the Company's contracts are either separate contracts or are not distinct from the existing contract due to the significant integration and interrelated tasks provided in the context of the contract. Modifications to add non-distinct services are accounted for as if they were part of the existing contract and recognized as a cumulative adjustment to revenue.

The Company performs an allocation of the transaction price when there is more than one performance obligation included in the same contract and the performance obligations are satisfied at different times. Allocation of the total transaction price is determined based on the stand-alone selling price of each item relative to the total contract value. When stand-alone selling prices are not directly observable, the Company estimates stand-alone selling price using an expected cost-plus margin approach. The Company considers market conditions and historical data to estimate its costs plus a specified margin, which may be adjusted for differences in product, customers or other factors.

------

The timing of revenue recognition, billings and cash collection may result in contract assets, unbilled receivables or contract liabilities. Contract assets arise when revenue recognized exceeds the amount billed to customers and represent the Company's right to consideration that is subject to conditions other than the passage of time. Unbilled receivables arise when revenue recognized exceeds the amount billed to customers and represent the Company's unconditional right to consideration, for which only the passage of time is required. Contract liabilities arise when the Company receives consideration from customers in advance of providing goods or services and represent the Company's obligations to satisfy performance obligations. Contract liabilities are recognized as revenue when (or as) the performance obligations are satisfied. Contract assets and unbilled receivables are generally classified as current assets, and contract liabilities are generally classified as current liabilities, in the consolidated balance sheets. Contract assets are presented within prepaid and other current assets in the consolidated balance sheets.

***Cost of Revenue***

The cost of revenue primarily consists of labor, including direct labor and third-party specialist subcontractors, materials and equipment costs related to delivering the Company's products and services, allocated facility costs and warranty expenses. Allocated facility costs primarily include depreciation and amortization expenses, information technology costs and facility occupancy costs. Costs of products and services are recorded as or when control of products is transferred to the customer, and as services are performed.

***Research and Development***

Research and development expenses primarily consist of personnel-related costs, including salaries, benefits and stock-based compensation costs, costs of materials, costs of consultants and allocated facility costs associated with the research, engineering, design and development of the Company's quantum computing technologies. Allocated facility costs primarily include depreciation and amortization expenses, information technology costs and facility occupancy costs. Research and development costs are expensed as incurred.

***Selling, general and administrative***

Selling, general and administrative expenses primarily consist of personnel-related costs, including salaries, benefits and stock-based compensation costs, for executive leadership and employees bid, proposal, marketing, sales, legal, finance, accounting, human resources, information technology and other administrative functions. In addition, these expenses include allocated facility costs and costs of consultants performing similar functions. Selling, general and administrative costs are expensed as incurred.

***Stock-Based Compensation***

The Company accounts for stock-based compensation in accordance with ASC 718, *Compensation – Stock Compensation*. The Company's stock-based compensation awards are all equity-classified and consist of stock options and restricted stock awards ("RSA"). The Company has sufficient authorized but unissued common shares to satisfy all of the convertible redeemable preferred stock conversions and stock-based compensation awards. Stock-based compensation cost is measured based on the fair value of the awards as determined on the grant date. The Company recognizes stock-based compensation expense using the graded attribution method in which expense is recognized on a straight-line basis over the requisite service period for each separately vesting portion of the stock option or RSA as if the award was, in substance, multiple awards. The Company accounts for forfeitures as they occur.

The fair value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires extensive use of accounting judgment and financial estimates, including estimates of the fair value of the underlying common stock, the expected term participants will retain their vested stock options before exercising them, the estimated volatility of the common stock price over the expected term, the risk free rate and expected dividend yield. The fair value of restricted stock awards is determined based on the estimated fair market value of the Company's common stock on the grant date. The Company's common stock is not publicly traded and therefore quoted market prices are not available. Accordingly, fair market value is determined through an independent third-party valuation using a probability weighted expected return method. The valuation considers several factors requiring extensive use of judgement, including recently completed equity transactions, historical and forecasted financial performance, selection of peer companies, the estimated value and probability of future equity transactions and other relevant qualitative and quantitative inputs.

***Impairment of Long-Lived Assets***

Long-lived assets such as property and equipment, right-of-use assets and intangible assets with identifiable useful lives are reviewed for impairment when events or changes in circumstances indicate that the carrying value of the asset or asset group may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for impairment, the Company first compares the total estimated future undiscounted cash flows expected to be generated from the asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent the carrying amount of the asset exceeds its fair value. No impairment loss related to long-lived assets was recognized for the year ended December 31, 2025. An impairment loss of $12.0 million was recognized for the year ended December 31, 2024, of which $11.6 million was attributed to intangible assets acquired in the SiNoptiq and Morton acquisitions completed in 2024. Additional information is provided in Note 6 – *Intangible Assets.*

------

***Accounting for Government Grants***

As discussed under "Accounting Pronouncements Recently Issued or Adopted," the FASB issued ASU 2025-10 in December 2025, which will establish authoritative GAAP for government grants. The guidance will be effective for public business entities for annual periods beginning after December 15, 2028, and for all other business entities for annual periods beginning after December 15, 2029. The Company is currently evaluating the extent of the impact of ASU 2025-10 on its consolidated financial statements.

Until the guidance becomes effective and consistent with the Company's approach prior to the issuance of ASU 2025-10, the Company will continue to apply International Accounting Standard 20, *Accounting for Government Grants and Disclosure of Government Assistance* ("IAS 20"), by analogy.

Under IAS 20, a government grant is recognized when there is reasonable assurance (analogous to "probable" as defined in GAAP) that the Company will comply with the conditions attached to the grant and the grant will be received. Grants are recognized in earnings on a systematic basis over the periods in which the related qualifying expenses are incurred and distinguished between grants related to assets and grants related to income. For a grant related to income that has met recognition criteria, the grant is recognized at the same time as the corresponding expense is incurred. For grants related to assets, the grant is recognized as the related asset is reflected in earnings, generally as depreciation is recognized on the related asset.

The Company records government grants in accordance with the nature of the grant, and depending on the nature of the grant, IAS 20 permits recognition either (i) separately under a general heading such as other income, (ii) as a reduction of the related expense or (iii) as a reduction of the cost of the related asset. For both grants related to assets and income, the Company has elected to present such income separately within grant income to distinguish it from other operating items.

Generally, government arrangements accounted for as grant income are those where the Company does not have an obligation to provide the government entity with a good or service that qualifies as a performance obligation, including the transfer of control of intellectual property ("IP") and where the governmental entity has agreed to fund only a portion of the costs incurred subject to a cap. Deliverables in government grant contracts are limited to providing the government entity with a means for evaluating the progress and effectiveness of the project and do not transfer ownership of products, prototypes or rights to intellectual property. Arrangements with governmental entities that obligate the Company to provide a prototype product, research paper, pre-existing IP or newly created IP or other form of deliverable are accounted for as revenue.

***Total other income, net***

Total other income, net includes interest income, changes in the fair value of SAFE liabilities and contingent consideration and other, net. Other, net consists primarily of income from refundable research and development tax credits, interest expense related to borrowings and gains or losses resulting from fluctuations in exchange rates during the reporting period on unsettled transactions and outstanding balances with foreign subsidiaries, vendors or customers. During the year ended December 31, 2025, the total Other, net primarily consists of $1.1 million of research and development tax credits recognized by the Company.

***Income Taxes***

Income taxes are accounted for under the asset and liability method. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Current and deferred income taxes are measured based on the tax laws that are enacted as of the balance sheet date of the relevant reporting period. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts of assets and liabilities and their respective tax bases using tax rates in effect for the year in which the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statement of operations and comprehensive loss in the period when the change is enacted. A valuation allowance is established when it is more likely than not, based on available positive and negative evidence that some or all of the Company's deferred tax assets will not be realized.

The Company recognizes the effect of a tax position when it is more likely than not, based on technical merits, that the position will be sustained upon examination by the appropriate taxing authorities. The amount of tax benefit recognized for an uncertain tax position is the largest amount of benefit with a greater than 50 percent likelihood of being realized. Unrecognized tax benefits are included within other liabilities if recognized and are charged to earnings in the period that such determination is made. The Company records interest and penalties related to tax uncertainties, if applicable, as a component of income tax expense.

***Related Party Transactions***

A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries' controls, is controlled by or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.

The consolidated financial statements include disclosure of material related party transactions, other than compensation arrangements, expense allowances and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of the accompanying consolidated financial statements is not required.

------

***Fair Value Measurements***

The carrying value of certain financial instruments held by the Company are measured at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. As a basis for considering such assumptions, the following hierarchy lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Level 1* – Observable inputs such as quoted prices (unadjusted) in active markets
that are accessible at the measurement date for identical assets or liabilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Level 2* – Observable inputs such as quoted prices for similar instruments in
active markets, quoted prices for identical or similar instruments in markets that are not active, or model-derived valuations whose significant inputs are observable; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Level 3* – Unobservable inputs that are significant to the measurement of fair
value but are supported by little to no market data, requiring the Company to develop its own assumptions.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurements. The Company's assessment of the significance of a particular input to the fair value measurement requires judgment and consideration of factors specific to the asset or liability.

Changes in assumptions or in market conditions could significantly affect the estimates. The Company determines whether transfers have occurred between levels in the fair value hierarchy by reassessing the inputs used in determining fair value at the end of each reporting period.

The following table sets forth the fair value of financial instruments that were measured at fair value on a recurring basis (in thousands):

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** |
|  | **2025** | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** | **2024** |
|  | **Level 1** | **Level 2** | **Level 3** | **Total** | **Level 1** | **Level2** | **Level 3** | **Total** |
|  **Financial Assets:** |  |  |  |  |  |  |  |  |
|  Money market funds | $6157 | $— | $— | $6157 | $42740 | $— | $— | $42740 |
|  Available-for-sale securities | $51475 | $— | $— | $51475 | $— | $— | $— | $— |
|  Total financial assets | $57632 | $— | $— | $57632 | $42740 | $— | $— | $42740 |
|  **Financial Liabilities:** |  |  |  |  |  |  |  |  |
|  Contingent obligation | $— | $— | $1828 | $1828 | $— | $— | $— | $— |
|  Total financial liabilities | $— | $— | $1828 | $1828 | $— | $— | $— | $— |

---

There were no transfers into or out of Level 3 of the fair value hierarchy during the year ended December 31, 2025.

The Company's contingent obligation is classified within Level 3 of the fair value hierarchy and is remeasured to fair value each reporting period. The fair value measurement relies primarily on the estimated fair value of the Company's stock, which is not publicly traded. Estimating the fair value of the Company's common stock requires management to assess the probability-weighted outcomes associated with remaining a private company and completing a Business Combination at each measurement date. At December 31, 2025, this unobservable input was assessed at 80% associated with completing the Business Combination. Refer to Note 12 – *Commitments and Contingencies* for information regarding the nature and accounting of the contingent obligation.

The Company's money market funds, presented within cash and cash equivalents on the consolidated balance sheets, are classified within Level 1 of the fair value hierarchy as the fair value is based on quoted prices in active markets. The Company's available-for-sale securities are classified within Level 1 of the fair value hierarchy as the fair value is based on quoted prices in active markets.

The Company's financial assets and liabilities that are not measured at fair value on a recurring basis consist of cash and cash equivalents (excluding the money markets funds in the table above), accounts receivable, accounts payable, accrued liabilities and deferred consideration payable. The carrying amounts of these financial assets and liabilities approximate their fair value due to the short-term nature of these instruments.

------

The Company's non-financial assets, which primarily consist of property and equipment, goodwill and intangible assets, are not required to be measured at fair value on a recurring basis and instead are reported at their cost basis. However, on a periodic basis whenever events or changes in circumstances indicate that their carrying amount may not be fully recoverable, non-financial assets are assessed for impairment. The fair value measurements, in such instances, are based on market participant assumptions which would fall within Level 3 of the fair value hierarchy.

***Foreign Currency Measurement and Translation***

The Company operates in the U.K. and Australia in the form of its wholly owned subsidiaries, ColdQuanta U.K. Ltd and ColdQuanta Australia PTY Limited, respectively. The functional currency of ColdQuanta U.K. Ltd is the British Pound Sterling (GBP), while ColdQuanta Australia PTY Limited's functional currency is the Australian Dollar (AUD). ColdQuanta U.K. Ltd has foreign currency transactions in U.S. dollars (USD), Euros (EUR) and Japanese Yen (JPY). ColdQuanta Australia PTY Limited has foreign currency transactions in USD. For both subsidiaries, foreign currency monetary assets primarily consist of bank accounts and accounts receivable, while foreign currency monetary liabilities primarily consist of accounts payable, all denominated in currencies other than each subsidiary's functional currency. Monetary assets and liabilities denominated in a currency other than each subsidiary's functional currency are remeasured into the functional currency using the exchange rate as of the balance sheet date. Non-monetary assets and liabilities are remeasured using historical exchange rates. Resulting foreign-currency transaction gains and losses are recognized in the consolidated statement of operations and comprehensive loss. Following remeasurement, the assets, liabilities, revenues and expenses of each foreign subsidiary are translated from the functional currency into USD, the Company's reporting currency. Assets and liabilities are translated at period-end exchange rates, and revenues and expenses at average rates. Translation adjustments are recorded in accumulated other comprehensive loss.

***Comprehensive Loss***

Comprehensive loss consists of net loss and other comprehensive income (loss), which principally includes unrealized income on available-for-sale securities and foreign currency translation adjustments. Accumulated other comprehensive income (loss) is reported as a component of stockholders' deficit.

***Loss Per Share***

Basic net loss per share attributable to common stockholders is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period.

Diluted net loss per share attributable to common stockholders is computed by dividing net loss by the weighted-average number of shares of common stock outstanding in the basic net loss per share calculation plus the number of potential shares of common stock that would be issued assuming exercise or conversion of all potentially dilutive securities. In periods with a reported net loss, the effects of anti-dilutive potential common shares are excluded and diluted net loss per share is equal to basic net loss per share.

**2. Revenue Recognition** 

As described in Note 1 – *Summary of Operations and Significant Accounting Policies*, the Company recognizes revenue at a point in time or over time consistent with how it satisfies its performance obligations and transfers control to its customers. Revenue from point-in-time contracts was $3.6 million and $3.0 million for the years ended December 31, 2025 and 2024, respectively. Revenue from over-time contracts was $28.9 million and $25.9 million for the years ended December 31, 2025 and 2024, respectively.

A receivable is recorded when the Company has an unconditional right to receive payment based on the satisfaction of performance obligations. Amounts for which the Company's right to consideration is conditional upon factors other than the passage of time are recorded as contract assets. The balance of accounts receivable was $9.5 million and $4.0 million as of December 31, 2025 and 2024, respectively as shown on the consolidated balance sheet.

A reconciliation of the beginning and ending balances of contract assets, unbilled receivables and contract liabilities for the year is shown in the table below (in thousands):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** |
|  | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** |
|  | **Unbilled**<br>**Receivables** | **Contract**<br>**Assets** | **Contract**<br>**Liabilities** | **Unbilled**<br>**Receivables** | **Contract**<br>**Assets** | **Contract**<br>**Liabilities** |
|  Beginning of the year | $3558 | $— | $3402 | $1304 | $— | $2551 |
|  Unbilled receivables additions | 29766 |  |  | 15711 |  |  |
|  Contract assets additions |  | 201 |  |  |  |  |
|  Amounts transferred to receivables | (28590) |  |  | (13457) |  |  |
|  Customer advance payments |  |  | 11436 |  |  | 3525 |
|  Revenue recognized |  |  | (7968) |  |  | (2674) |
|  **End of the year** | $**4734** | $**201** | $**6871** | $**3558** | $**—** | $**3402** |

---

------

The Company expects to recognize revenue of $23.4 million and $0.2 million from remaining performance obligations that are unsatisfied (or partially unsatisfied) for non-cancelable contracts in the years ending December 31, 2026 and December 31, 2027, respectively. The increase in contract assets, unbilled receivables and contract liabilities from 2024 to 2025 were primarily driven by the timing of revenue recognition, customer billings and advance payments associated with the increased revenue activity during the year.

***Disaggregated Revenue***

Revenue from government customers comprised 81% and 80% of total revenue for the years ended December 31, 2025 and 2024, respectively.

The Company's revenues disaggregated by customer location is as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Year ended December 31,** | **Year ended December 31,** |
|  | **2025** | **2024** |
|  United States | $23204 | $12548 |
|  United Kingdom | 4107 | 11333 |
|  Japan | 2071 | 3784 |
|  Australia | 1816 | 146 |
|  Other | 1266 | 1025 |
|  **Total revenue** | $**32464** | $**28836** |

---

**3. Business Combination** 

***Morton Acquisition***

On January 25, 2024, the Company acquired 100% of the equity of Morton (the "Morton Acquisition"). Morton specialized in the development and manufacturing of advanced silicon photonics-based component and sub-system technologies. The acquisition date fair value purchase consideration of $3.9 million consisted of $2.6 million of cash, $0.4 million of common stock (1,179,246 shares at $0.37 per share), $0.4 million of contingent consideration and $0.5 million of other payments and adjustments.

The contingent consideration includes cash payments of $0.2 million and 1,725,415 restricted shares of issued and outstanding common stock subject to vesting based on the achievement of specified development milestones. The contingent consideration had an estimated fair value of $0.4 million at the acquisition date and was recognized as a liability. During the year ended December 31, 2024, 86,271 shares vested valued at $50 thousand and the Company paid $12 thousand in cash related to the contingent consideration. Changes in the Company's strategic direction during the second quarter of the year ended December 31, 2024 resulted in the decision not to integrate or further invest in the commercialization of the photonic business represented by the Morton Acquisition and the Company determined that it would not achieve the remaining specified development milestones underlying the contingent consideration. As a result, the Company de-recognized the liability and recognized a gain of $0.4 million, during the year ended December 31, 2024, related to the change in the fair value of the contingent consideration.

In May 2025, the Company amended the equity purchase agreement with the former Morton owners. The amendment added new milestones that, if achieved, require the Company to make the remaining contingent cash payments of approximately $0.2 million and result in the vesting of the remaining 1,639,145 outstanding shares of restricted common stock. The Company evaluated the guidance in ASC 805 and determined that this agreement should be accounted for separately from the Morton Acquisition. Additional information is provided in Note 12 – *Commitments and Contingencies.*

The acquisition agreement also provides for deferred employee compensation of $0.8 million comprised of 1,552,875 common shares and $0.2 million in cash, contingent on the continued employment of a key individual who is a former shareholder. These deferred payments have been accounted for as post-combination compensation expense and are excluded from the purchase consideration.

The acquisition was accounted for as a business combination, whereby the excess of the purchase consideration over the fair value of identifiable net assets was allocated to goodwill. The Company recognized intangible assets of $2.3 million of which $2.2 million represented in-process research and development. The goodwill of $1.5 million is associated with the acquired workforce and technical knowledge of that workforce that does not qualify as a separable intangible asset. In accordance with applicable jurisdictional tax rules, the goodwill recognized is deductible for income tax purposes. Additional information is provided in Notes *5 – Goodwill, 6 – Intangible Assets and 16 – Income Taxes.*

No additional impairment was recognized during the year ended December 31, 2025 as it relates to the Morton acquisition. During the year ended December 31, 2024, the Company recorded impairment charges to fully write down the carrying value of goodwill, intangible assets and other long-lived assets associated with this acquisition. Additional information is provided in Note 5—*Goodwill* and Note 6 – *Intangible Assets.*

------

**4. Available-for-sale Securities** 

The following table summarizes the unrealized positions of the Company's available-for-sale securities disaggregated by class of instrument as of December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** |
|  | **Amortized<br>Cost** | **Gross Unrealized<br>Gains** | **Gross<br>Unrealized<br>Losses** | **Fair<br>Value** |
|  US Treasury Securities | $12043 | $33 | $— | $12076 |
|  Corporate Debt | 39292 | 107 |  | 39399 |
|  **Total** | $**51335** | $**140** | $**—** | $**51475** |

---

The following table provides the amortized cost and fair value of the Company's available-for-sale securities by contractual maturity as of December 31, 2025:

---

| | | |
|:---|:---|:---|
|  | **Amortized Cost** | **Fair Value** |
|  Maturing within one year | $34244 | $34318 |
|  Maturing after one to two years | 17091 | 17157 |
|  **Total** | $**51335** | $**51475** |

---

Amortized cost includes accrued interest receivable on available-for-sale debt securities. There were no realized gains or losses on available-for-sale securities during 2025.

For marketable securities classified as available-for-sale that are in an unrealized loss position as of the balance sheet date, the Company assesses whether or not it intends to sell the security, or more-likely-than-not will be required to sell the security, before recovery of its amortized cost basis which would require a write-down to fair value through net loss. As of December 31, 2025, there were no available-for-sale debt securities in a loss position. An allowance for credit losses was not deemed necessary related to available-for-sale securities as of December 31, 2025. There were no marketable securities classified as available-for-sale as of December 31, 2024.

Refer to Note 1 – *Summary of Operations and Significant Accounting Policies (Fair Value Measurements)* for the Company's valuation techniques and fair value hierarchy disclosures.

**5. Goodwill** 

The Company performed its annual goodwill impairment assessments as of October 1, 2025 and 2024 using a qualitative approach. In evaluating whether it was more likely than not that the fair value of its single reporting unit was less than its carrying amount, management considered relevant events and circumstances including macroeconomic conditions, industry and market trends, cost factors, overall financial performance and entity-specific developments such as the indicated enterprise values from the commitment to financing transactions during 2025 and 2024. Based on this assessment, management concluded that it was not more likely than not that the fair value of its single reporting unit was less than its carrying amount. Accordingly, no quantitative impairment test was required, and no impairment of goodwill, except as described below related to the Morton Acquisition, was recognized for the years ended December 31, 2025 and 2024, respectively.

In the second quarter of 2024, the Company determined that it would not further invest in the activities of the acquired Morton business and thus it would not be integrated as originally planned. As a result, the Company identified indicators of impairment for the goodwill recognized in connection with the Morton Acquisition. In accordance with ASC 350, the Company recorded impairment charges to fully write down the carrying value of goodwill, intangible assets and other long-lived assets associated with this acquisition. The Company recognized a non-cash impairment charge of $1.5 million in 2024, equal to the full carrying amount of goodwill recognized in connection with the Morton Acquisition as the carrying value of the photonic reporting unit exceeded its fair value. Subsequent to the impairment, the Company determined that its business is comprised of one reporting unit.

Goodwill of $9.3 million from a prior business combination represents the Company's only goodwill balance as of December 31, 2025. The table below presents the changes in the carrying amount of goodwill (in thousands):

---

| | | |
|:---|:---|:---|
|  | **2025** | **2024** |
|  Beginning balance | $9315 | $9315 |
|  Goodwill additions |  | 1533 |
|  Goodwill impairment |  | (1533) |
|  **Ending balance** | $**9315** | $**9315** |

---

------

**6. Intangible Assets** 

On January 26, 2024, the Company acquired a photonic patent license from SiNoptiq, Inc. for a purchase price of $9.4 million, consisting of i) $4.8 million of Series B convertible redeemable preferred stock, representing 4,667,846 shares with a fair value of $1.0176 per share, ii) $2.2 million in cash, iii) $2.0 million in deferred cash payments, payable over two years in four scheduled installments with the first payment of $0.5 million completed in 2024, which has been included in deferred consideration payable in the consolidated balance sheet and iv) $0.4 million in other adjustments, which includes an indemnity escrow amount, transaction expenses incurred by both the acquiree and the Company for legal, tax, accounting and financial advisory services in connection with the asset acquisition and the settlement of pre-existing indebtedness between the Company and seller.

The asset acquisition also provided for payments of cash up to $1.5 million and 1,474,056 restricted shares of Series B convertible redeemable preferred stock that are contingent upon the achievement of certain sales-and development-based milestones. The cash portion of these contingent payments is further dependent on the Company closing a round of equity financing at a level defined in the purchase agreement. At the acquisition date, the Company assessed the likelihood of the contingencies being met as not probable, and based on management's ongoing assessment, the Company continues to conclude that the likelihood of the contingencies being met is not probable.

During the second quarter of 2024, in consideration of the change in strategic direction, management determined that the intangible asset arising from the above asset acquisition and the intangible assets acquired in the Morton Acquisition no longer have substantive future economic benefits. The Company recognized an impairment charge equal to the full carrying amount of these intangible assets of $11.6 million during the year ended December 31, 2024. There were no intangible asset impairments during the year ended December 31, 2025.

Intangible assets from prior business combinations, which represent the Company's only intangible assets, are included in other assets on the consolidated balance sheet. The intangible asset balances and accumulated amortization are as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
|  | **Gross<br>Carrying<br>Value** | **Accumulated<br>Amortization** | **Net of<br>Accumulated<br>Amortization** | **Weighted-<br>Average<br>Remaining<br>Amortization<br>Period (in<br>years)** |
|  Customer relationships | $41 | $25 | $16 | 2.33 |
|  Tradename | 127 | 78 | 49 | 2.33 |
|  | $**168** | $**103** | $**65** |  |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
|  | **Gross<br>Carrying<br>Value** | **Accumulated<br>Amortization** | **Net of<br>Accumulated<br>Amortization** | **Weighted-<br>Average<br>Remaining<br>Amortization<br>Period (in<br>years)** |
|  Customer relationships | $41 | $18 | $23 | 3.33 |
|  Tradename | 127 | 57 | 70 | 3.33 |
|  Software | 162 | 162 |  | 0.00 |
|  Order backlog | 2 | 2 |  | 0.00 |
|  | $**332** | $**239** | $**93** |  |

---

Amortization expense of $28 thousand and $98 thousand were recognized during the year ended December 31, 2025 and December 31, 2024, respectively.

The table below presents the estimated amortization expense on intangible assets for the next five years and thereafter as of December 31, 2025 (in thousands):

---

| | |
|:---|:---|
| 2026 | $28 |
| 2027 | 28 |
| 2028 | 9 |
| 2029 |  |
| 2030 |  |
|  Thereafter |  |
|  **Total estimated amortization expense** | $**65** |

---

------

**7. Inventories** 

Major classifications of inventories are as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **As of December 31,** | **As of December 31,** |
|  | **2025** | **2024** |
|  Raw materials | $2930 | $2204 |
|  Work-in-process | 1369 | 19 |
|  **Total inventories** | $**4299** | $**2223** |

---

**8. Prepaid Expenses and Other Current Assets** 

Prepaid expenses and other current assets consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **As of December 31,** | **As of December 31,** |
|  | **2025** | **2024** |
|  Prepaid expenses | $2834 | $2759 |
|  Deferred offering costs | 6384 |  |
|  Grant receivable | 562 |  |
|  Contract assets | 201 |  |
|  Other current assets | 55 | 436 |
|  **Total prepaid expenses and other current assets** | $**10036** | $**3195** |

---

**9. Property and Equipment, Net** 

Property and equipment, net consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **As of December 31,** | **As of December 31,** |
|  | **2025** | **2024** |
|  Computers and equipment | $12030 | $10454 |
|  Quantum computer | 3614 | 3614 |
|  Leasehold improvements | 1432 | 1221 |
|  Furniture and fixtures | 390 | 217 |
|  Software and website | 1381 | 684 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total property and equipment** | 18847 | 16190 |
|  Accumulated depreciation and amortization | (10598) | (6872) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total property and equipment, net of depreciation** | 8249 | 9318 |
|  Assets not in service | 425 | 697 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total property and equipment, net** | $8674 | $10015 |

---

For the years ended December 31, 2025 and 2024, depreciation expenses were $3.7 million and $2.5 million, respectively. Depreciation expense is included within the consolidated statement of operations and comprehensive loss as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Years Ended December 31,** | **Years Ended December 31,** |
|  | **2025** | **2024** |
|  Cost of revenue | $638 | $100 |
|  Research and development | 2403 | 2285 |
|  Seling, general and administrative | 623 | 133 |
|  **Total depreciation expense** | $**3664** | $**2518** |

---

***Long-lived assets by geographic area***

The following table presents the Company's long-lived assets by geographic area, which includes property and equipment, net and operating lease right of use assets (in thousands):

---

| | | |
|:---|:---|:---|
|  | **As of December 31,** | **As of December 31,** |
|  | **2025** | **2024** |
|  United States | $10052 | $12443 |
|  United Kingdom | 3219 | 2972 |
|  Australia | 326 |  |
|  **Total** | $**13597** | $**15415** |

---

------

**10. Accrued Liabilities** 

Accrued liabilities consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **As of December 31,** | **As of December 31,** |
|  | **2025** | **2024** |
|  Accrued compensation and benefits | $3680 | $1923 |
|  Goods and services received, not yet invoiced | 1847 | 3932 |
|  Accrued contingent payments | 1828 |  |
|  Accrued offering costs | 731 |  |
|  Series C convertible redeemable preferred stock unpaid issuance costs |  | 2650 |
|  Other accruals | 524 | 773 |
|  **Total accrued liabilities** | $**8610** | $**9278** |

---

**11. SAFE Notes** 

There were no SAFE Notes outstanding as of December 31, 2025, and no related activity occurred during the year then ended. The Company issued SAFE Notes during the period from December 2023 through May 2024, all of which were settled in December 2024.

The Company issued a series of SAFE Notes to multiple investors for total cash proceeds of $24.0 million, comprising $1.4 million in 2023 and $22.6 million in 2024, with identical terms for each issuance. SAFE Notes are financing instruments that provide investors with the right to receive equity upon a future financing event.

Management evaluated the SAFE Notes under ASC 480, *Distinguishing Liabilities from Equity*, and determined that they are a liability under ASC 480, do not meet the definition of a derivative and do not qualify for equity classification. Given the variation in possible share prices of the future equity financing, the SAFE Notes represent an obligation to issue a variable number of shares for a fixed monetary amount. Accordingly, the SAFE Notes are accounted for as nonderivative financial liabilities, initially recognized at fair value with subsequent remeasurement at each reporting date. Any changes in fair value will be recognized in earnings and any issuance costs related to the SAFE Notes will be expensed immediately as incurred.

On December 27, 2024, the Company settled the SAFE Notes with total aggregate face amount of $24.0 million. Upon settlement, the SAFE Notes were measured at a fair value of $26.4 million and exchanged for 22,869,771 shares of Series C-1 convertible redeemable preferred stock. The carrying amount of the SAFE Notes was derecognized and the new shares of Series C-1 convertible redeemable preferred stock were recorded within temporary equity at fair value. The Company remeasured the SAFE Notes at the date of settlement and recorded a loss of $1.9 million, resulting in an aggregate loss of $2.4 million for the year ended December 31, 2024.

**12. Commitments and Contingencies** 

***Contingent Payments***

In May 2025, the Company amended the equity purchase agreement related to the Morton Acquisition. The amendment added new milestones that, if achieved, requires the Company to make the remaining contingent cash payments of approximately $0.2 million and results in the vesting of the remaining 1,639,145 outstanding shares of restricted common stock. Additional information regarding the original purchase agreement and related contingent consideration is provided in Note 3 – *Business Combinations.*

The contingent obligation is classified as a liability and is remeasured at fair value each reporting period, with changes in fair value recognized in earnings. Refer to Note 1 – *Summary of Operations and Significant Accounting Policies* (Fair Value Measurements) for information regarding the valuation methodology and significant unobservable inputs used in measuring the contingent obligation. At the date of the amendment, the Company assessed the likelihood that the milestones related to the contingent payments would be met and recognized a contingent obligation measured at fair value, with a corresponding expense recorded in selling, general and administrative expenses in the consolidated statement of operations and comprehensive loss. Subsequent to the amendment, certain milestones were achieved, and the Company settled $2.3 million of the contingent obligation, consisting of $0.1 million in cash payments and the vesting of 948,979 shares of restricted common stock with an estimated fair value of $2.2 million. During the year ended December 31, 2025, a total of $4.1 million of selling, general and administrative expenses related to the contingent obligation was recognized in the consolidated statement of operations and comprehensive loss. The remaining balance of the contingent obligation included in accrued liabilities on the consolidated balance sheet was $1.8 million as of December 31, 2025.

***Indemnification***

In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representation, failure to perform or claims and losses arising from certain events as outlined within the particular contract. The Company has also entered into indemnification agreements with certain of its officers and directors.

------

The Company's maximum exposure under such indemnities is unknown and has not been estimated, as this would involve future claims that may be made against the Company that have not occurred. To date, the Company has not made any payments related to these indemnities and believes the risk of material obligations under these indemnities to be remote. Accordingly, the Company has not accrued any liabilities related to such indemnification obligations in the consolidated financial statements.

***Product Warranties***

As described in Note 1 – *Summary of Operations and Significant Accounting Policies*, the Company issues one-year product warranties on its commercial product sales as a guarantee of the intended functionality of such products. Accruals related to these warranty obligations were immaterial for the years ended December 31, 2025 and 2024.

***Legal Matters***

From time to time, the Company may become involved in certain legal proceedings and claims incidental to the normal course of its business. As of December 31, 2025 and 2024, management is not aware of any pending or threatened litigation that could have a material impact on the consolidated financial statements.

***Exclusive License Agreement with University of Wisconsin***

In October 2019, the Company entered into an exclusive license agreement with the Wisconsin Alumni Research Foundation (WARF) (the WARF License Agreement). Under the WARF License Agreement, the Company is granted an exclusive (subject to standard carve-outs), worldwide, sub-licensable license, in all fields, to make, have made, use, have used, offer for sale, sell, have sold and import products and services that would be covered by the patents listed in the WARF License Agreement. The WARF License Agreement provides the Company with exclusive rights to the listed patents, subject to certain WARF reservations.

In consideration for the rights granted under the WARF License Agreement, the Company paid a $50 thousand license fee and will pay an earned royalty on the net sales of products, including a pass-through of sales-based royalties on sublicensee sales, a sublicense consideration percentage for sublicenses executed on or before December 31, 2022 and annual minimum royalties per calendar year. These are first due within the Company's fiscal year 2026 and creditable against that year's earned royalties.

***Exclusive License Agreement with University of Colorado***

In June 2021, the Company entered into an exclusive license agreement with the Regents of the University of Colorado (the "Exclusive CU License Agreement"). Under the Exclusive CU License Agreement, the Company is granted an exclusive (subject to standard carve-outs), worldwide, sub-licensable license, in all fields, to make, have made, use, have used, offer for sale, sell, have sold and import products and services that would be covered by the patents listed in the Exclusive CU License Agreement.

The Exclusive CU License Agreement provides the Company with exclusive rights to the listed patent portfolio in all fields, subject to (a) reserved rights for CU and other non-profit employers of the inventors and authors of the licensed patents and software and other research institutions to use the inventions for research, education, clinical and non-commercial purposes and (b) U.S. Government rights in federally funded intellectual property under the Bayh-Dole Act and other regulations.

In consideration for the rights granted under the Exclusive CU License Agreement, the Company paid a $130 thousand license fee, and will pay annual license maintenance fees (creditable against royalties), a royalty on net sales of non-software products in the low single digits, with royalties on sales to the government fluctuating by a single digit percentage, depending on volume, a royalty on net sales of licensed software products in the mid-single digits and a sublicense revenue percentage share in the low double digits for sublicenses (with higher rates for sublicenses executed in the first or second year).

***Non-Exclusive License Agreement with the University of Colorado***

In February 2012, the Company entered into a non-exclusive license agreement with the Regents of the University of Colorado (the "Non-Exclusive CU License Agreement"), as amended. Under the Non-Exclusive CU License Agreement, the Company is granted a non-exclusive, worldwide license, in all fields to make, use, sell, offer for sale, lease and import products and processes that would infringe certain licensed patents co-owned with, or solely owned by, SRI International, Inc. listed in the Non-Exclusive CU License Agreement. The Non-Exclusive CU License Agreement also grants the Company to CU's know how related to such patents. The license grant in the preceding sentence is exclusive as to CU's interests in the patents listed in the Non-Exclusive CU License Agreement. The Non-Exclusive CU License Agreement is predicated on an inter-institutional agreement, pursuant to which the CU obtained the right to grant us the licenses under the Non-Exclusive CU License Agreement from SRI International, Inc.

The Non-Exclusive CU License Agreement provides the Company rights to the listed patent portfolio subject to reserved rights for CU to the Company's own research and education, SRI International's rights to the patents and U.S. Government rights under the Bayh-Dole Act and other regulations. In consideration for the rights granted under the Non-Exclusive CU License Agreement, the Company will pay a royalty on net sales.

------

**13. Convertible Redeemable Preferred Stock** 

***Series Seed Convertible Redeemable Preferred Stock***

In 2018, the Company issued 24,871,033 shares of Series Seed convertible redeemable preferred stock at an original issue price of $0.2714 per share for $6.5 million, net of issuance costs of $0.2 million. No Series Seed convertible redeemable preferred stock shares were issued during the years ended December 31, 2025 and 2024.

***Series Seed II Convertible Redeemable Preferred Stock***

In 2019 and 2020, the Company issued 27,499,984 shares of Series Seed II convertible redeemable preferred stock at an original issue price of $0.38 per share. The financing for the Series Seed II convertible redeemable preferred stock was performed over three rounds. The first round occurred in November 2019, when 13,749,995 shares were issued for $5.2 million, net of issuance costs of $40 thousand. The other two rounds occurred in April and July 2020, when the remaining 13,749,989 shares were issued for $5.2 million with no additional issuance costs. No Series Seed II convertible redeemable preferred stock shares were issued during the years ended December 31, 2025 and 2024.

***Series A Convertible Redeemable Preferred Stock***

In 2020, the Company issued 101,515,976 shares of Series A convertible redeemable preferred stock at an original issue price of $0.3628 per share for $36.7 million, net of issuance costs of $0.2 million. No Series A convertible redeemable preferred stock shares were issued during the years ended December 31, 2025 and 2024.

***Series B and Series B-1 Convertible Redeemable Preferred Stock***

During 2022, the Company issued 107,814,417 shares of Series B convertible redeemable preferred stock at an original issue price of $1.0176 per share for $109.7 million, resulting in net proceeds of $107.4 million after legal issuance costs. In the same year, the Company issued 32,419,574 shares of Series B-1 convertible redeemable preferred stock at an original issue price of $0.6420 per share for $20.8 million, which was subsequently adjusted to $33.0 million to reflect the change in the fair value of the related embedded derivative liability. Total issuance costs associated with Series B and B-1 convertible redeemable preferred stock were $1.9 million. On January 26, 2024 the Company issued 6,141,902 shares of Series B convertible redeemable preferred stock as consideration to the seller in the Company's acquisition of SiNoptiq, Inc. No Series B or B-1 convertible redeemable preferred stock shares were issued during the year ended December 31, 2025.

***Series C and Series C-1 Convertible Redeemable Preferred Stock***

On December 27, 2024, the Company issued 20,508,938 shares of Series C convertible redeemable preferred stock at an original purchase price of $1.234 per share for proceeds of $25.3 million. As noted in Note 10 – *SAFE Notes*, the Company converted all of its issued and outstanding SAFE Notes valued at $26.4 million into 22,869,771 shares of Series C-1 convertible redeemable preferred stock at an issue price of $1.05 per share, in accordance with the terms of the SAFE Notes and recorded in temporary equity. Total issuance costs associated with Series C and C-1 convertible redeemable preferred stock was $2.8 million.

On April 11, 2025 the Company issued 35,032,081 shares of Series C convertible redeemable preferred stock at an original purchase price of $1.234 per share for proceeds of $43.2 million. On May 8, 2025 the Company issued 4,858,933 shares of Series C convertible redeemable preferred stock at an original purchase price of $1.234 per share for proceeds of $6.0 million. No issuance costs were incurred with Series C convertible redeemable preferred stock issued during the year ended December 31, 2025.

The Company's convertible redeemable preferred stock is classified as temporary equity and initially recorded at fair value which is determined to be the net proceeds of the transaction. The Company's Series Seed, Seed II, A, B, B-1, C and C-1 convertible redeemable preferred stock (collectively "convertible redeemable preferred stock") are not currently redeemable or probable of becoming redeemable in the future period.

The convertible redeemable preferred stock contains the following rights:

***Dividends***

The holders of the Company's convertible redeemable preferred stock are entitled to receive non-cumulative cash dividends at a rate of 6% of the original issue price of each series per year only if and when declared by the Board of Directors in preference to holders of common stock. Series B, Series B-1, Series C and Series C-1 convertible redeemable preferred stock are entitled to receive the non-cumulative cash dividends in preference to holders of the Company's Series Seed, Series Seed II and Series A convertible redeemable preferred stock.

The Company has not declared any dividends through years ended December 31, 2025 and December 31, 2024.

***Voting Rights***

Holders of all convertible redeemable preferred stock are entitled to the number of votes equal to the number of shares of the Company's common stock into which such holder's shares are convertible.

------

***Election of Board of Directors***

Holders of Series C and C-1 convertible redeemable preferred stock are entitled to elect one of the members of the Company's Board of Directors. Holders of Series B and B-1 convertible redeemable preferred stock are entitled to elect two of the members of the Company's Board of Directors. Holders of Series Seed II and Series Seed convertible redeemable preferred stock are entitled to elect one director. The holders of all convertible redeemable preferred stock are entitled to elect one of the members of the Company's Board of Directors. Two directors are elected by holders of common stock.

***Conversion Rights***

Each share of convertible redeemable preferred stock is initially convertible into one fully paid and non-assessable share of the Company's common stock at the option of the holder, at any time, and without payment of additional consideration and is mandatorily convertible upon the occurrence of certain events. The conversion price is initially equal to the applicable original issue price of each series and could be adjusted for events such as dilutive issuances, stock splits, combinations, mergers or reorganizations.

There were no conversions of convertible redeemable preferred stock into common stock during the years ended December 31, 2025 and 2024.

***Redemption Rights***

The convertible redeemable preferred stock contains provisions which provide the holders with the option to redeem the shares upon a voluntary or involuntary liquidation, dissolution, winding up or Deemed Liquidation Event such as a merger, sale, lease transfer or other disposition of all or substantially all the assets of the Company. These provisions are considered contingent redemption provisions that are not solely within the control of the Company and are deemed to be not probable. Accordingly, the convertible redeemable preferred stock is presented outside of permanent equity in mezzanine equity of the consolidated balance sheet.

***Liquidity Preference***

In the event of any Liquidation Event or Deemed Liquidation Event, holders of Series C, C-1, B and B-1 convertible redeemable preferred stock are entitled to receive, prior to and in preference to holders of Series Seed, Series Seed II, Series A and common stock, an amount equal to the greater of (i) the applicable Original Issue Price plus any declared but unpaid dividends and (ii) the amount per share as would have been payable had all shares of Series B, B-1, C and C-1 convertible redeemable preferred stock been converted into Common Stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If the residual assets are insufficient to pay the convertible and redeemable preferred shareholders the full amount, holders of the Series B, B-1, C and C-1 convertible redeemable preferred stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be paid in full.

The Company's convertible redeemable preferred stock consists of the following (in thousands, except share data):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** |
| **Convertible Redeemable**<br> **Preferred Stock** | **Shares<br>Authorized** | **Shares Issued<br>and<br>Outstanding** | **Carrying<br>Amount** | **Aggregate<br>Liquidation<br>Preference** |
|  Series Seed | 24871033 | 24871033 | $6526 | $6750 |
|  Series Seed II | 27499984 | 27499984 | 10411 | 10450 |
|  Series A | 101515976 | 101515976 | 36658 | 36830 |
|  Series B | 113956319 | 113956319 | 112145 | 115962 |
|  Series B-1 | 32419574 | 32419574 | 32990 | 20813 |
|  Series C | 60777953 | 60399952 | 71733 | 74534 |
|  Series C-1 | 22869771 | 22869771 | 26351 | 23988 |
|  **Total Convertible Redeemable Preferred Stock** | **383910610** | **383532609** | $**296814** | $**289327** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As of December 31, 2024** | **As of December 31, 2024** | **As of December 31, 2024** | **As of December 31, 2024** |
| **Convertible Redeemable**<br> **Preferred Stock** | **Shares<br>Authorized** | **Shares Issued<br>and<br>Outstanding** | **Carrying<br>Amount** | **Aggregate<br>Liquidation<br>Preference** |
|  Series Seed | 24871033 | 24871033 | $6526 | $6750 |
|  Series Seed II | 27499984 | 27499984 | 10411 | 10450 |
|  Series A | 101515976 | 101515976 | 36658 | 36830 |
|  Series B | 113956319 | 113956319 | 112145 | 115962 |
|  Series B-1 | 32419574 | 32419574 | 32990 | 20813 |
|  Series C | 60777953 | 20508938 | 22503 | 25308 |
|  Series C-1 | 22869771 | 22869771 | 26351 | 23988 |
|  **Total Convertible Redeemable Preferred Stock** | **383910610** | **343641595** | $**247584** | $**240101** |

---

------

**14. Common Stock** 

The voting, dividend and liquidation rights of holders of common stock are subject to and qualified by the rights, powers and preferences of the holders of convertible redeemable preferred stock. Holders of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the majority of holders of outstanding shares of the Company's capital stock.

On December 27, 2024, in connection with the Series C and Series C-1 convertible redeemable preferred stock issuances, the Amended and Restated Certificate of Incorporation granted the Company authority to issue 573,000,000 shares of common stock, $0.0001 par value per share.

**15. Stock-Based Compensation** 

***Stock Incentive Plan***

In July 2017, the Company approved and adopted the 2017 Stock Incentive Plan (Voting), which authorized the granting of incentive and nonqualified stock options, restricted stock and other stock awards to employees, officers, directors, consultants and advisors. In connection with the Company's incorporation in the state of Delaware in June 2018, the original equity incentive plan was continued as the 2017 Stock Incentive Plan (the "Plan"). As of December 31, 2025 and December 31, 2024, 153,037,164 shares of common stock were reserved for issuance under the Plan.

The exercise term, exercise price and vesting conditions for stock option grants are determined by the Company's Board of Directors. Under the terms of the Plan, options may not be granted at an exercise price less than the fair value of the common stock on the grant date. In the case of incentive stock options, for individuals holding more than 10% of the voting power of all classes of outstanding stock of the Company, the exercise price must be at least 110% of the fair value of the common stock on the grant date. In the absence of trading on a national or regional exchange, the fair value of the Company's common stock is determined by the Board of Directors.

The Company has the right of first refusal to repurchase shares in the event a stockholder proposes to transfer shares acquired under the Plan to a third party. Under the terms of the Plan and form of option agreement, the Company has the right to repurchase all, but not less than all, of the shares on the same terms and conditions as those offered to the third party. The Company's right of first refusal expires within thirty days of the Company receiving notice of the stockholder's proposed transfer. Under the terms of the Plan and form of option agreement, the Company's right of first refusal terminates in its entirety on the first date that the Company's common stock is listed on an established national or regional stock exchange.

Following termination of a Plan participant's service for any reason, the Company has the right to repurchase all of the shares that the participant has acquired or will acquire, pursuant to awards granted under the Plan, at a repurchase price equal to the fair value of the shares, as determined by the Board of Directors. Vested options held at the date of a participant's termination may generally be exercised within ninety days. The Company's repurchase right generally expires one year after the participant's termination date or, if the terminated participant exercises vested options post-termination in accordance with the terms of the Plan, one year after the participant's post-termination exercise date. Under the terms of the Plan, the Company's repurchase right terminates in its entirety on the first date that the Company's common stock is listed on an established national or regional stock exchange. The Company's policies prohibit the repurchase of stock resulting from exercised stock options where the stock option had been vested for less than six months.

Awards granted under the Plan are service-based awards typically vesting over a period of three to four years from the date of grant. The vesting schedules typically contain both cliff vesting and graded vesting. All options granted have a contractual term of ten years, following the date of grant.

***Stock Options***

In November 2025, in preparation for completion of the Business Combination, certain members of the Board of Directors resigned. As part of their separation, the Board of Directors approved the immediate vesting of any unvested options held by the separated directors and provided an extension to the post-separation exercise period following their resignation. The changes constituted modifications of the awards' terms, resulting in modification accounting under ASC 718, *Compensation – Stock Compensation*. The additional compensation expense resulting from the modifications was immaterial to the financial statements as of and for the period ended December 31, 2025.

------

The following table summarizes the Company's stock option activity (in thousands, except share and per share amounts):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Number of<br>Options** | **Weighted Avg<br>Exercise Price** | **Weighted Avg<br>Remaining<br>Contractual<br>Life (Years)** | **Aggregate**<br>**Intrinsic Value** |
|  **Outstanding as of December 31, 2023** | **100272113** | $**0.15** | **7.8** | $**15891** |
|  Granted | 43241076 | $0.31 |  |  |
|  Exercised | (5223413) | $0.20 |  |  |
|  Forfeited/Cancelled | (43227230) | $0.18 |  |  |
|  **Outstanding as of December 31, 2024** | **95062546** | $**0.21** | **7.2** | $**35180** |
|  Granted | 5382161 | $0.58 |  | $— |
|  Exercised | (4714295) | $0.21 |  |  |
|  Forfeited/Cancelled | (5648323) | $0.26 |  |  |
|  **Outstanding as of December 31, 2025** | **90082089** | $**0.23** | **6.2** | $**203691** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **As of December 31, 2024** | **As of December 31, 2024** | **As of December 31, 2024** | **As of December 31, 2024** | **As of December 31, 2024** |
|  Exercisable | 77771189 | $0.20 | 5.8 | $29566 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** |
|  Exercisable | 79966798 | $0.21 | 5.9 | $182598 |

---

The aggregate intrinsic value in the table above represents the difference between the exercise price of the underlying stock options and the fair value of the Company's common stock for the respective date. The total intrinsic value of options exercised during the years ended December 31, 2025 and 2024 was $2.9 million and $0.9 million, respectively. The total grant date fair value of options vested during the year ended December 31, 2025 and 2024 was $2.8 million and $2.1 million, respectively.

***Significant Assumptions Used to Estimate Fair Value***

The Company estimates the fair value of stock options on the grant date using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option.

The following assumptions were used to estimate the fair value of stock options granted and modified during the years ended December 31:

---

| | | |
|:---|:---|:---|
|  | **2025** | **2024** |
|  Expected volatility | 46.4% - 128.0% | 45.8% -70.6% |
|  Expected term (in years) | 0.75 - 6.06 | 5.00 - 10.00 |
|  Risk-free interest rate | 3.6% - 4.2% | 0.4% - 3.2% |
|  Dividend yield | -% | -% |

---

*Expected volatility –* Expected volatility measures the uncertainty about the realization of expected future returns that was estimated based on the implied and historical volatility of the share price of publicly-traded peer companies over the expected term.

*Expected term –* The expected term of the Company's options represents the period that the awards are expected to be outstanding. The Company uses the simplified method to estimate the expected term.

*Risk-free interest rate –* The risk-free interest rate is based on the U.S. Treasury rate in effect on the date of grant with a term equal to the expected term of each option.

*Dividend yield –* The Company has not paid dividends in the past and does not anticipate paying dividends on its common stock in the foreseeable future. Accordingly, the Company used an expected dividend yield of zero.

*Fair value of underlying common stock –* The absence of a public market for the Company's common stock for the years ended December 31, 2025 and 2024 required the Company's Board of Directors to estimate the fair value of its common stock. The Company's Board of Directors considered a number of objective and subjective factors, including third party valuations of its common stock, the valuation of comparable companies, sales of the Company's convertible redeemable preferred stock to outside investors in arms-length transactions, the Company's operating and financial performance, the lack of marketability and general and industry specific economic factors.

For the year ended December 31, 2025, the Board of Directors, with the assistance of third-party valuation specialists, estimated the fair value of the Company's common stock using a probability-weighted expected return method, which considered multiple potential future outcomes and their probability-weighted expected equity values. The valuation reflected assumptions based on facts and circumstances as of December 31, 2025, including the Company's expectations regarding the timing and likelihood of the consummation of the Business Combination described in Note 1 – *Summary of Operations and Significant Accounting Policies*.

------

***Restricted Stock***

Effective May 10, 2022 (the "Super.tech Closing Date"), the Company acquired 100% of the equity and voting interests of Super.tech pursuant to the terms of an agreement and plan of merger dated as of May 6, 2022. In connection with the acquisition, the Company issued common shares to the sellers subject to a make-whole obligation. The shares issued in connection with the acquisition may be automatically forfeited, along with any dividends declared by the Board, by the holders if the founders do not continue involvement as an employee or consultant over at least two years from the Super.tech Closing Date. Accordingly, the Company has accounted for the consideration as compensation in the form of restricted shares.

In January 2024, the Company acquired 100% of the equity of Morton. In connection with the acquisition, the Company issued restricted stock awards to the sellers subject to certain vesting conditions. Refer to Note 3 – *Business Combination* for further information. During the year ended December 31, 2025, certain restricted shares issued in connection with the Morton acquisition vested upon the achievement of specified contingent payment milestones. See Note 12 – *Commitments and Contingencies* for additional information regarding the contingent payment arrangement.

The table below presents the activity of the restricted stock awards ("RSAs"):

---

| | | |
|:---|:---|:---|
|  | **RSAs**<br>**Outstanding** | **Weighted Average<br>Grant Date Fair<br>Value** |
|  **Unvested as of December 31, 2023** | **2657090** | $**0.09** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Granted | 3278290 | 0.31 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vested | (2743360) | 0.10 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Forfeited |  |  |
|  **Unvested as of December 31, 2024** | **3192020** | $**0.31** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Granted |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vested | (1984229) | 0.31 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Forfeited |  |  |
|  **Unvested as of December 31, 2025** | **1207791** | $**0.31** |

---

***Compensation Cost***

Total stock-based compensation expense is included within the consolidated statement of operations and comprehensive loss as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2025** | **2024** |
|  Cost of revenue | $300 | $104 |
|  Research and development | 374 | 447 |
|  Selling, general and administrative | 2382 | 3190 |
|  **Total stock-based compensation expense** | $**3056** | $**3741** |

---

***Unvested Stock Options and RSAs***

As of December 31, 2025, unrecognized stock-based compensation expense related to unvested stock option awards was $1.8 million, which the Company expects to recognize over a weighted-average period of 2.5 years. Unrecognized stock-based compensation expense related to unvested restricted stock awards as of December 31, 2025 was $0.4 million, all of which is expected to be recognized within the year ending December 31, 2026.

**16. Income Taxes** 

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the transparency of income tax disclosures by requiring additional disaggregation in the effective tax rate reconciliation and disclosures of income taxes paid by jurisdiction. The guidance does not change the recognition or measurement of income taxes. The Company adopted ASU 2023-09 effective January 1, 2025, on a prospective basis. The adoption impacted the Company's income tax disclosures but did not have a material impact on its consolidated financial statements.

On July 4, 2025, the U.S. H.R.1, an act to provide for reconciliation pursuant to title II of H. Con. Res. 14. (the "OBBBA") was enacted. The OBBBA introduces multiple tax law and other legislative changes, including modifications to income tax provisions such as existing 21% corporate income tax rate made permanent, domestic research and development expenses, the restoration of 100% bonus depreciation, changes to Section 163(j) interest limitations and U.S. taxation of international earnings; the repeal or acceleration of the sunset of certain tax credits under the 2022 Inflation Reduction Act and elimination of certain penalties for violations of certain regulatory credit programs. We have recognized the effects of the OBBBA provisions in our financial results to the extent they are applicable to the year ended December 31, 2025.

------

The following table sets forth loss before taxes and the expense (benefit) for income taxes:

---

| | | |
|:---|:---|:---|
|  | **Years Ended December 31,** | **Years Ended December 31,** |
|  | **2025** | **2024** |
|  Loss before income taxes: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. | $(30426) | $(52256) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Foreign | (1369) | (1508) |
|  **Total loss before income taxes** | $**(31795)** | $**(53764)** |
|  Current income tax expense (benefit): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Federal |  | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; State |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Foreign |  |  |
|  **Total current income tax expense (benefit)** | $**—** | $**(2)** |
|  Deferred income tax expense (benefit): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Federal |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; State |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Foreign |  |  |
|  **Total deferred income tax expense (benefit)** | $**—** | $**—** |
|  Income tax expense (benefit) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Federal | $— | $(2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; State |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Foreign |  |  |
|  **Total income tax expense (benefit)** | $**—** | $**(2)** |

---

Income taxes paid (net of refunds received) were immaterial for federal, state, and foreign jurisdictions for the years ended December 31, 2025 and 2024.

Upon adoption of ASU 2023-09, Improvements to Income Tax Disclosures, the reconciliation of taxes at the federal statutory rate to our provision for (benefit from) income taxes for the year ended December 31, 2025 was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Years Ended December 31,** | **Years Ended December 31,** | **Years Ended December 31,** | **Years Ended December 31,** |
|  | **2025** | **2025**<br>**Effective Tax<br>Rate** | **2024** | **2024**<br>**Effective Tax**<br>**Rate** |
|  U.S. federal statutory income tax | $(6677) | 21.00% | $(11290) | 21.00% |
|  State and local income taxes<sup>1</sup> | (38) | 0.12% | (110) | 0.21% |
|  Foreign tax effects | 284 | -0.89% | (55) | 0.10% |
|  Non-deductible expenses | 232 | -0.74% | 123 | -0.23% |
|  Change in valuation allowance (Federal and State) | 6077 | -19.11% | 10323 | -19.20% |
|  Return to provision adjustment | 32 | -0.10% | 252 | -0.47% |
|  Rate difference | 61 | -0.19% | 675 | -1.26% |
|  Others | 29 | -0.09% | 80 | -0.15% |
|  **Total tax (benefit) expense** | $**—** | **0.00%** | $**(2)** | **0.00%** |

---

<sup>1</sup> The states and local jurisdictions that contribute to the majority (greater than 50%) of the tax effect in this category include Colorado, Florida, Illinois and Wisconsin. 

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2025** | **Effective Tax<br>Rate** |
|  Foreign tax effects |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United Kingdom |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Statutory tax rate difference between United Kingdom and United States | (65) | 0.21% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in Valuation Allowance | 400 | -1.26% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Statutory tax rate difference between Australia and United States | 9 | -0.03% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in Valuation Allowance | (60) | 0.19% |
|  **Total tax (benefit) expense - foreign tax effects** | $**284** | **-0.89%** |

---

------

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities are as follows:

---

| | | |
|:---|:---|:---|
|  | **As of December 31,** | **As of December 31,** |
|  | **2025** | **2024** |
|  **Deferred tax assets:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net operating loss carryforwards | $26732 | $21930 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Capitalized §174 R&D expense | 17031 | 13983 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock-based compensation expense | 1011 | 817 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Research and development credits | 391 | 391 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Operating lease ROU liability | 471 | 182 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Plant, Property, & Equipment | 315 | 104 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other | 223 | 259 |
|  Total deferred tax assets | 46174 | 37666 |
|  Valuation allowance | (45713) | (37646) |
|  **Total deferred tax assets net of valuation allowance** | **$461** | $**20** |
|  **Deferred tax liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Operating lease ROU asset | (417) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other | (14) | (20) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unrealized Gain - OCI | (30) |  |
|  Total deferred tax liabilities | $(461) | $(20) |
|  **Net deferred tax assets** | $**—** | $**—** |

---

Temporary differences giving rise to deferred tax assets consisted primarily of U.S. federal and state net operating loss carryforwards and U.S. federal research and development tax credit carryforwards. As of December 31, 2025 and 2024, the Company has U.S. federal net operating loss carryforwards of $117.4 million and $104.0 million, respectively, all of which can be carried forward indefinitely. As of December 31, 2025 and December 31, 2024, the Company has U.S. federal research and development tax credit carryforwards of $0.4 million which will begin to expire in 2034. The Company has various state net operating loss carryforwards. The determination of state net operating losses depends on apportionment percentages. State tax laws can change from year to year and impact the amount of such carryforwards.

Future realization of the tax benefits of existing temporary differences and carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of December 31, 2025, the Company performed an evaluation to determine whether a valuation allowance was needed. Based on the Company's analysis, which considered all available evidence, both positive and negative, the Company determined that it is not more likely than not that its net deferred tax assets will be realized. Accordingly, the Company maintained a full valuation allowance as of December 31, 2025. The valuation allowance increased by $6.1 million in 2025 primarily due to current year operating losses.

In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (or the Code), a corporation that undergoes an "ownership change," generally defined as a greater than 50% change by value in its equity ownership over a three-year period, is subject to limitations on its ability to utilize its pre-change net operating losses ("NOLs") and its research and development credit carryforwards to offset future taxable income. The Company's existing NOLs and research and development credit carryforwards may be subject to limitations arising from previous ownership changes. If the Company undergoes, or is deemed to have previously undergone, an ownership change, the Company's ability to utilize NOLs and research and development credit carryforwards could be limited (perhaps substantially) by Sections 382 and 383 of the Code. Additionally, future changes in the Company's stock ownership, some of which might be beyond the Company's control, could result in an ownership change under Section 382 of the Code. For these reasons, in the event the Company experiences or is deemed to have experienced an "ownership change" for these purposes, the Company may not be able to utilize a material or even a substantial portion of the NOLs and research and development credit carryforwards, even if the Company attains profitability. The Company has not completed a Code Section 382 analysis regarding any limitation on its NOLs carryforwards. As of December 31, 2025 and December 31, 2024, the Company has U.K. net operating loss carryforward of $7.8 million and $6.2 million respectively. The net operating loss can be carried forward indefinitely.

To the extent penalties and interest would be assessed on any underpayment of income tax, the Company's policy is that such amounts would be accrued and classified as a component of income tax expense in the consolidated financial statements. For the year ended December 31, 2025, there were no amounts recognized relating to interest and penalties, nor were there any uncertain income tax positions.

------

The Company files U.S federal and state income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending federal or state income tax examinations. As a result of the Company's net operating loss carryforwards, the Company's federal and state statutes of limitations remain open for all years until the net operating loss carryforwards are utilized or expire prior to utilization.

The transition tax in the Tax Act imposed a tax on undistributed and previously untaxed foreign earnings at various tax rates. This tax largely eliminated the differences between the financial reporting and income tax basis of foreign undistributed earnings. Furthermore, as of December 31, 2025, foreign withholding taxes have not been provided on unremitted earnings of subsidiaries operating outside of the U.S. as these amounts are considered to be indefinitely reinvested.

The Company accounts for the tax effects of global intangible low-taxed income ("GILTI") as a component of income tax expense in the period the tax arises, to the extent applicable. The U.S. Treasury Department issued final regulations in July 2020 concerning global intangible low income, commonly referred to as GILTI tax and introduced by the Tax Act of 2017. The GILTI provisions impose a tax on foreign income in excess of a deemed return on tangible assets of foreign corporations. The final tax regulations allow income to be excluded from GILTI tax that are subject to an effective tax rate higher than 90 percent of the U.S. tax rate. An accounting policy choice is allowed to either treat taxes due on future U.S. inclusions related to GILTI in taxable income as a current-period expense when incurred (the "period cost method") or factor such amounts into the measurement of deferred taxes (the "deferred method"). The calculation of the deferred balance with respect to the new GILTI tax provisions will depend, in part, on analyzing global income to determine whether future U.S. inclusions in taxable income are expected related to GILTI and, if so, what the impact is expected to be. The Company's accounting policy election is to treat the taxes due on future U.S. inclusions in taxable income under GILTI as a period cost when incurred. Therefore, it has not recorded deferred taxes related to GILTI on the Company's foreign subsidiary.

**17. Leases** 

Cash paid for operating lease was $1.8 million and $1.4 million for the years ended December 31, 2025 and 2024, respectively. Operating lease expense was $1.0 million and $1.7 million for the years ended December 31, 2025 and 2024, respectively.

Weighted average remaining lease terms and discount rates for operating leases were as follows:

---

| | | |
|:---|:---|:---|
|  | **As of December 31,** | **As of December 31,** |
|  | **2025** | **2024** |
|  Weighted-average remaining lease term (in years) | 6.28 | 5.85 |
|  Weighted-average discount rate | 8.04% | 8.47% |

---

The amount of undiscounted future minimum lease payments as of December 31, 2025 is as follows (in thousands):

---

| | |
|:---|:---|
|  | **Total Lease<br>Payments** |
| 2026 | $1504 |
| 2027 | 1025 |
| 2028 | 955 |
| 2029 | 941 |
| 2030 | 576 |
|  Thereafter | 1605 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total lease payments** | **6606** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Less: Present value adjustment | (1456) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Present value of lease liabilities** | $**5150** |

---

**18. Related Party Transactions** 

***Transactions with Universities***

**University of Colorado-Boulder** 

The Company considers the University of Colorado-Boulder to be a related party because the Company's Co-Founder and Chief Science Officer concurrently serves as a professor at the University of Colorado-Boulder. The Company sponsors research projects and utilizes laboratory equipment at the University of Colorado-Boulder. Under these contracts, the Company recognized service revenue of $0 and $0.1 million, and cost of services of $0.1 million and $0.1 million during the years ended December 31, 2025 and December 31, 2024, respectively. Expenses relate to research and development and use of laboratory equipment. There were no accounts receivable or accrued liabilities outstanding as of December 31, 2025 and 2024.

------

**University of Wisconsin-Madison** 

The Company's Chief Scientist for Quantum Information concurrently serves as a professor at the University of Wisconsin-Madison. In his role as a researcher and professor at the university, he has been granted patents held by WARF. Additionally, in June 2016, the Company entered into a research agreement with the Board of Regents of the University of Wisconsin System on behalf of the University of Wisconsin-Madison to provide research, data and findings in accordance with the terms of the contract and subsequent amendments. The Company recorded $0.5 million of research and development expenses in each of the years ended December 31, 2025 and 2024. Total accrued liabilities of $0.3 million and $0.5 million were outstanding as of December 31, 2025 and December 31, 2024, respectively. As of December 31, 2025, the Company had incurred $4.4 million of its total $4.6 million committed funding.

***Other Transactions***

In June 2025, the Company announced a new go-to-market partnership with SAIC, an investor in the Company's Series C-1 convertible redeemable preferred stock. SAIC provides advanced technology solutions to solve and support mission-critical needs across military, intelligence and government agencies. Through this partnership, the Company is expanding the deployment of quantum sensing technologies, including atomic clocks, quantum RF communication and inertial sensing, into defense and aerospace applications.

The Company engages a patent attorney, who is a related party to an officer of the Company, for the preparation and filing of patent applications and other patent-related legal matters. Fees of $0 and $88 thousand were billed by the attorney for patent legal services rendered during the years ended December 31, 2025 and 2024, respectively. There were no accounts payable outstanding as of December 31, 2025 and 2024.

The Company entered into a consulting agreement with the spouse of a member of the Company's management to provide consulting services on various research and development and customer contracts. The Company paid $190 thousand and $41 thousand in 2025 and 2024, respectively. There were no accounts payable outstanding as of December 31, 2025 and 2024.

The Company occasionally enters into consulting agreements with members of the Company's Board of Directors and/or investors in the Company to serve in executive roles based on the business' needs. In 2025, Infleqtion entered into a consulting agreement with Grant Dollens, a member of Infleqtion's Board of Directors and the previous Interim Chief Financial Officer of Infleqtion. Under the terms of the agreement, Mr. Dollens provides financial and accounting services to the Infleqtion and receives compensation at a rate of $15 thousand per month. Under this agreement, Infleqtion paid Mr. Dollens $213 thousand and $45 thousand in the year ended December 31, 2025 and 2024. Total accounts payable of $36 thousand and $0 were outstanding as of December 31, 2025 and December 31, 2024, respectively,

During 2025, the Company engaged DRS Daylight Solutions, Inc., ("DRS Daylight") to provide engineering and programming services to the Company. At that time, Mr. Day, was a member of the Company's Board of Director and served as an executive of DRS Daylight. Mr. Day subsequently departed DRS Daylight and joined Monarch Quantum, a company controlled by Mr. Day, and the Company transitioned the services agreement to Monarch. Under the terms of these arrangements, Mr. Day provides engineering and programming services to the Company. Total accounts payable of $1.8 million is outstanding as of December 31, 2025. No amounts were paid during the year ended December 31, 2025.

On December 21, 2025, Eric Bjornholt was appointed to the Company's Board of Directors. Mr. Bjornholt serves as the Chief Financial Officer of Microchip Technology Inc. During the year ended December 31, 2025, the Company purchased laboratory equipment from Microchip Technology Inc. Total accounts payable of $64 thousand were outstanding as of December 31, 2025. No payments were made during the year ended December 31, 2025.

**19. Loss Per Share** 

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. The following table sets forth the computation of basic net loss per share attributable to common stockholders (in thousands, except share and per share amounts):

---

| | | |
|:---|:---|:---|
|  | **Years Ended December 31,** | **Years Ended December 31,** |
|  | **2025** | **2024** |
|  **Numerator:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net loss attributable to common stockholders | $(31795) | $(53764) |
|  **Denominator:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weighted average shares used in computing net loss per share attributable to common stockholders – basic | 46185671 | 39808027 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net loss per share attributable to common stockholders - | $(0.69) | $(1.35) |

---

Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding in the basic net loss per share calculation plus the number of potential shares of common stock that would be issued assuming exercise or conversion of all potentially dilutive securities. For the years ended December 31, 2025 and 2024, diluted net loss per share is the same as basic net loss per share as the inclusion of potentially dilutive shares would have been anti-dilutive.

------

The following table summarizes the outstanding shares of potentially dilutive securities that were excluded from the computation of diluted net loss per share attributable to common stockholders, as their effect would be anti-dilutive:

---

| | | |
|:---|:---|:---|
|  | **Years Ended December 31,** | **Years Ended December 31,** |
|  | **2025** | **2024** |
|  Common stock options outstanding | 90082089 | 95062546 |
|  Convertible redeemable preferred stock outstanding | 383532609 | 343641595 |
|  Unvested restricted common stock awards | 1207791 | 3192020 |
|  **Total** | **474822489** | **441896161** |

---

The restricted stock awards, while legally outstanding, are not considered participating securities as any rights to dividends during the vesting period are forfeitable.

**20. Segment Information** 

The Company derives revenues from customers by providing quantum computing solutions to its government and commercial customers from multiple locations throughout the world, but manages the business activities on a consolidated basis. The Company's Chief Executive Officer is the chief operating decision maker ("CODM"). Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by CODM.

The CODM reviews financial information on a consolidated basis for the purposes of making operating decisions, allocating resources and evaluating financial performance. Accordingly, the Company determined that it operates in a single operating and reportable segment.

The measure used by the CODM to assess performance and make operating decisions is net income or loss as reported on the consolidated statements of operations and comprehensive loss. The Company's consolidated net income or loss is used by the CODM to identify underlying trends in the performance of the business and compare the Company's financial performance against competitors.

Significant expense categories reviewed by the CODM include cost of revenue, research and development and selling, general and administrative expenses. Other segment items consist of the remaining income and expense items presented in the consolidated statement of operations and comprehensive loss. Total assets reviewed by the CODM are those presented on the consolidated balance sheets and purchases of property and equipment reviewed by the CODM are those reported on the consolidated statements of cash flows.

Refer to Note 1 – *Summary of Operations and Significant Accounting Policies* for information regarding significant customer concentrations and Note 2 – *Revenue Recognition* for revenue by geographic area.

**21. Subsequent Events** 

The Company has evaluated subsequent events through March 31, 2026, the date the consolidated financial statements were available to be issued.

*Churchill Capital Corp X Business Combination* 

The Business Combination closed on February 13, 2026. Refer to Note 1 – *Summary of Operations and Significant Accounting Policies* for additional information.

*ARPA-E Contract* 

In January 2026, the Company entered into a cost-sharing agreement with the U.S. Department of Energy's Advanced Research Projects Agency-Energy ("ARPA-E"). The agreement was executed after December 31, 2025 and did not result in any recognized amounts in the consolidated financial statements as of that date.

## Exhibit 99.2

**Exhibit 99.2** 

**INFLEQTION'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF** 

**FINANCIAL CONDITION AND RESULTS OF OPERATIONS** 

*The following discussion and analysis of the financial condition and results of operations of ColdQuanta, Inc. (d/b/a/ Infleqtion) ("the Company," "Legacy Infleqtion," "we," "us" and "our") should be read together with our audited financial statements as of and for the years ended December 31, 2025 and 2024, together with the related notes thereto, included elsewhere in this Current Report on Form 8-K/A. Unless the context otherwise requires, references to "Infleqtion" refer to ColdQuanta Inc. (d/b/a/ Infleqtion) prior to the completion of the business combination, and to Infleqtion Inc. following the completion of the business combination. The following discussion contains forward-looking statements that reflect future plans, estimates, beliefs and expected performance. The forward-looking statements are dependent upon events, risks and uncertainties that may be outside of our control. Our actual results may differ significantly from those projected in the forward-looking statements.* 

**Overview** 

Our vision is to harness the power of quantum to expand human potential.

We are developing and commercializing quantum technology products as part of a full-stack platform, which currently includes offerings such as quantum sensing, quantum computing and software. Our quantum-enabled solutions are focused on addressing the world's most pressing challenges, with technologies actively deployed across a number of sectors today, including defense and security, AI, energy optimization, space and frontier, materials discovery and cybersecurity. Our approach is grounded in an integrated quantum technology platform, from foundational technology to advanced hardware and propriety software, all built on neutral atoms, nature's ideal qubits, which enable an adaptable, scalable and high-fidelity path to quantum advantage across multiple applications.

Today, our high-performance quantum clocks and quantum radio frequency ("RF") sensors are already delivering quantum advantage, such as sensing the world with superior precision relative to classical state-of-the-art systems, and unlocking new classes of national security and commercial applications. We are also pioneering the development of next-generation quantum inertial and gravimetric sensors for GPS-denied environments, including in space and underwater. Our sensing and timing products are designed to function outside laboratory settings and are targeted for real-world deployment. These products are complemented by our flagship quantum computing system, Sqale, a room-temperature quantum computer with demonstrated high fidelity (99.73% controlled-Z ("CZ") gate), the industry's largest neutral atom array outside of a research institution. As of December 31, 2025, the Company has achieved 12 logical qubits. Our quantum sensors and computers are supported by our proprietary software, Superstaq, which serves as a control panel for future hybrid quantum-classical workflows. In addition, we have developed CML software, based on quantum physics principles, that significantly amplifies AI performance today on classical graphics processing units ("GPUs").

We work with a diverse set of customers and strategic partners globally, serving organizations in national security, critical national infrastructure, scientific discovery and advanced computing sectors. Our partners and customers include the U.S. Department of Defense, DARPA, NASA, SAIC, Lockheed Martin, NVIDIA and the UK National Quantum Computing Centre. We generate revenue today through multiple channels and are scaling a global pipeline of strategic engagements.

We operate our business as a single operating and reportable segment. This determination is based on how the chief operating decision maker ("CODM"), our Chief Executive Officer, manages the business for the purpose of assessing performance and resource allocation.

------

**Recent Developments** 

***Business Combination with Churchill Capital Corp X***

On February 13, 2026, pursuant to the definitive agreement and plan of merger and reorganization (the "Merger Agreement"), dated September 8, 2025, with Churchill Capital Corp X, a publicly traded special purpose acquisition company ("CCX"), AH Merger Sub I, Inc., a direct wholly owned subsidiary of CCX, merged with and into Infleqtion, with Infleqtion continuing as the surviving corporation. Immediately thereafter, the surviving corporation merged with and into AH Merger Sub II, LLC ("Merger Sub II"), another direct wholly owned subsidiary of CCX, with Merger Sub II (renamed as "Infleqtion Quantum, LLC") continuing as the surviving entity and a wholly owned subsidiary of CCX (collectively, the "Business Combination"). In connection with the closing of the Business Combination on February 13, 2026 (the "Closing"), CCX changed its name to Infleqtion, Inc.

Immediately prior to the Closing, each issued and outstanding share of Legacy Infleqtion common stock, preferred stock and restricted stock was automatically surrendered and exchanged for the right to receive shares of CCX common stock, par value $0.0001 per share, based on a defined exchange ratio of 0.3470312 (the "Exchange Ratio"), representing shares of Infleqtion, Inc. common stock following the Closing.

Immediately following the Closing, there were approximately 216.5 million shares of Infleqtion, Inc. common stock issued and outstanding. Of these shares, approximately 151.8 million shares were issued to former holders of Infleqtion securities in respect of such securities, representing approximately 70.1% of the voting rights of Infleqtion, Inc. following the Closing.

In connection with the Closing, CCX delivered approximately $551.4 million of gross transaction proceeds to Infleqtion, consisting of approximately $424.8 million of proceeds from the trust account and approximately $126.5 million of proceeds from a previously announced private investment in public equity (the "PIPE Investment"). The PIPE Investment was completed pursuant to subscription agreements entered into on September 8, 2025, under which CCX issued an aggregate of 12,654,760 shares of common stock for total gross proceeds of $126.5 million. As of December 31, 2025, there were an aggregate of 10,425,000 CCX warrants outstanding, consisting of 10,350,000 public warrants and 75,000 private placement warrants. The outstanding CCX warrants transferred to Infleqtion upon Closing of the Business Combination and remain outstanding and equity classified instruments. Total direct and incremental transaction costs incurred by CCX and Infleqtion in connection with the Business Combination were approximately $35.8 million.

In addition, in connection with the Business Combination, holders of 37,821 CCX Class A ordinary shares exercised their redemption rights, representing approximately 0.09% of the outstanding CCX Class A ordinary shares, resulting in approximately $0.4 million being removed from the trust account.

Although CCX is the legal acquirer in the Business Combination, for financial accounting and reporting purposes under generally accepted accounting principles in the United States ("GAAP"), Infleqtion is the accounting acquirer and CCX is treated as the acquired company. Accordingly, the Business Combination is accounted for as a reverse recapitalization. Under this accounting treatment, the transaction is treated as the equivalent of Infleqtion issuing equity for the net assets of CCX, accompanied by a recapitalization. The net assets of CCX will be recorded at historical cost, which is expected to approximate fair value. As a result, no goodwill or other intangible assets will be recognized, and the historical operations presented prior to the Business Combination will be those of Infleqtion.

At the Closing, Infleqtion became the accounting acquirer and the successor registrant with the Securities and Exchange Commission (the "SEC"). Accordingly, Infleqtion's historical financial statements will be presented for all periods in future periodic reports filed with the SEC, beginning with the quarter ended March 31, 2026.

***ARPA-E Contract***

In January 2026, the Company entered into a cost-sharing agreement with the U.S. Department of Energy's Advanced Research Projects Agency-Energy ("ARPA-E"). The agreement was executed subsequent to December 31, 2025 and, as of that date, had not resulted in any recognized amounts in the Company's consolidated financial statements. Accordingly, the agreement did not impact the Company's results of operations or financial condition for the year ended December 31, 2025.

------

***Public Company Costs***

As a result of the Business Combination, Infleqtion became a publicly traded company and is subject to ongoing public company reporting, governance and compliance requirements. Accordingly, the Company expects to incur increased ongoing costs related to public company regulatory requirements and customary practices, including additional personnel, directors' and officers' liability insurance, director compensation, and additional internal and external accounting, legal and administrative resources, including increased audit and legal fees. These costs are expected to continue in future periods.

***Acquisition Activities***

On January 25, 2024, Infleqtion acquired 100% of the equity of Morton Photonics, Inc. ("Morton Photonics") in exchange for total consideration of $3.9 million (the "Morton Acquisition"). Morton Photonics specialized in the development and manufacturing of advanced silicon photonics-based component and sub-system technologies that enable microwave photonics, sensing systems and applications of these technologies in government and commercial systems. Morton Photonics also developed ultra-low noise semiconductor lasers, from commercially available discrete lasers with world-leading performance to fully integrated silicon photonics versions on multiple fabrication platforms, currently being optimized for operation at quantum wavelengths. These critical technologies were planned to drive photonic innovations and help develop our quantum radio frequency products and photonics and have implications for automotive LIDAR and 5G networks.

On January 26, 2024, Infleqtion acquired a photonic patent license from SiNoptiq, Inc. ("SiNoptiq") in exchange for total consideration of $9.4 million. SiNoptiq specialized in delivering leading photonics performance with its ultra-low loss silicon nitride platform. As silicon nitride is a critical foundational platform for quantum applications, enabling high-performance photonic lasers and the application of photonics to quantum solutions from the visible to the mid-infrared, this acquisition was planned to position us to integrate lasers, photonic, and atomic systems with our sensors and quantum computers, as well as bolster the quantum supply chain.

Subsequent to the Morton and SiNoptiq acquisitions in the first quarter of 2024, Infleqtion determined that it would not further invest in the commercialization of the photonics business represented by the Morton Acquisition and thus it would not be integrated as originally planned. Given the same change in strategic direction, management determined that the intangible assets arising from the SiNoptiq asset acquisition and intangible assets acquired in the Morton acquisition no longer have substantive future economic benefits. As a result, during the year ended December 31, 2024, we recorded an impairment charge of $1.5 million, equal to the full carrying amount of the goodwill recognized in connection with the Morton Acquisition, as well as intangible asset impairments of $11.6 million associated with these acquisitions.

***Contract Awards and Significant Funding***

*Contract Awards* 

In September 2025, NASA awarded us a $17.0 million contract modification, bringing the total contract value to $20.0 million, for the development of a Quantum Gravity Gradiometer ("QGG") for space deployment in the initial phase of NASA's QGG Pathfinder program, for which we are the prime sensor developer and integrator for this groundbreaking space-based gravity sensor.

In March 2025, the U.S. Army awarded us a $2.0 million contract related to its Linchpin AI program. This award significantly expands our pipeline for our contextual machine learning technology stack.

In March 2025, we announced that we were awarded $6.2 million in funding for the first quantum technology award under the U.S. Department of Energy's Advanced Research Projects Agency-Energy to develop quantum-enhanced solutions for energy grid optimization.

In September 2024, we were awarded $11.0 million in funding from the U.S. Department of Defense as part of the APFIT program. This award will support our work with Tiqker at the forefront, driving advancements in precision timing solutions—critical for enhancing military operational readiness, secure communications and mission success in contested environments. Collectively, this funding will support a range of defense areas, including assured communications, GPS-denied navigation, anti-spoof timing and synchronization for emerging technologies.

------

*Funding* 

In May 2025, we completed the final Series C convertible redeemable preferred stock offering with aggregate gross proceeds of approximately $100 million. The total raised includes $24.0 million in SAFEs issued in 2023 and 2024 that were converted into 22,869,771 shares of Series C-1 convertible redeemable preferred stock on December 27, 2024. The round was backed by a blend of strategic and institutional investors, including Glynn Capital, Counterpoint Global (Morgan Stanley), S32 and SAIC (who also entered into a go-to-market partnership with us). We are utilizing the proceeds to scale our quantum computing, sensing and precision timing systems, accelerating the deployment of field-ready solutions across defense, aerospace and national-security domains, and for general corporate purposes.

***Strategic Partnerships***

In December 2025, we announced our strategic partnership with Safran Electronics & Defense ("Safran") to advance quantum-enabled precision timing solutions for critical global infrastructure. Integrating our Tiqker quantum optical clock technology with Safran's trusted synchronization systems enables a GPS-independent timing architecture designed to withstand the most challenging environments. Through this partnership, we are advancing quantum innovation to transform mission-critical operations across defense, aerospace and telecommunications, establishing a new benchmark for secure, resilient, and ultra-precise timing capabilities.

In November 2025, we announced our strategic partnership with Voyager Technologies, Inc. to advance dual-use quantum technology in low-Earth orbit and beyond. The collaboration marks a major milestone in the growing convergence of the quantum and aerospace industries. Through this partnership, we are unlocking a completely new class of dual-use capabilities with quantum timing, sensing and computing in space, strengthening the backbone of next-generation space infrastructure and ensuring mission continuity in increasingly contested domains.

In October 2025, we announced a groundbreaking partnership with NVIDIA to deploy a NVQLink-enabled quantum supercomputing system at the Illinois Quantum & Microelectronics Park. Through this partnership, we are integrating our Sqale quantum computers with NVIDIA's GPU-accelerated systems via NVQLink, creating a unified architecture that enables real-time hybrid quantum–classical computing. This collaboration unlocks new possibilities in materials science, clean energy, secure communications and artificial intelligence, while addressing critical scalability challenges for quantum computing.

In June 2025, we announced a new go-to-market partnership with SAIC, a leading mission integrator that provides advanced technology solutions to solve and support mission-critical needs across military, intelligence and government agencies. Through this partnership, we are expanding the deployment of quantum sensing technologies, including atomic clocks, quantum RF communication and inertial sensing, into defense and aerospace applications.

The Company expects that these strategic partnerships will support future growth by expanding market access, enabling joint development opportunities, and accelerating elements of its product and technology roadmaps. While certain partnerships may create opportunities to generate revenue or enhance commercialization pathways, the timing and ultimate financial impact on the Company's results of operations, including revenue and gross profit, remain subject to a variety of factors, including customer adoption, program execution and market conditions.

**Trends and Key Factors Affecting Performance** 

Our business has demonstrated continued top-line growth, with revenue increasing to $32.5 million for the year ended December 31, 2025, compared to $28.8 million for the year ended December 31, 2024. The completion of our Series C convertible redeemable preferred stock financing further strengthened our financial position by providing capital to scale our quantum computing, sensing, and precision timing platforms, accelerate the deployment of field-ready solutions across defense, aerospace and national-security markets, and support general corporate purposes. Management believes this capital base enhances our ability to advance product innovation and pursue additional market opportunities, supporting our long-term growth strategy. In addition, as discussed above under 'Business Combination with Churchill Capital Corp X,' the completion of the Business Combination in February 2026 materially strengthened the Company's liquidity position. The following discussion highlights key trends and factors affecting our performance.

------

***Technology Milestones***

Many of our contracts with customers are dependent on our ability to demonstrate the technological feasibility of our products and services, as well as research and development of technology for clocks, quantum hardware and software, and materials science applications. These milestones include demonstrating materials science applications for high-fidelity quantum simulations, released CML capabilities to optimize hybrid quantum-classical workflows, and expanding our portfolio of deployable Tiqker optical clocks for military and aerospace customers. We risk the potential that our technology may become obsolete, as advancements in quantum technologies occur rapidly, necessitating additional investments. Additionally, integrating new technologies into our existing capabilities creates additional risks, such as compatibility with existing systems. Our business is dependent on our ability to achieve technological milestones while navigating these risks effectively.

Across our technology organization, generative AI ("GenAI") adoption has significantly enhanced productivity, particularly for software engineering as many of the mechanical aspects of software development have been replaced or accelerated by GenAI tooling, dramatically reducing the time required to complete repetitive, manual processes. In other less mechanical software development areas of our business which are deeply grounded in scientific research, GenAI serves as an accelerant.

***Government Funding***

A significant portion of our business is conducted with various governments, including agencies of the U.S., UK, Australian and Japanese governments. Changes in government spending levels and the timely funding thereof could impact our financial performance. The long-term outlook for our business is influenced by government funding priorities, the diversity of our programs and customers, and our ability to evolve our products and services and successfully execute on our contracts. Strong international demand for our products and services presents opportunities for our business, particularly in the United Kingdom.

During the year ended December 31, 2025, approximately 60%, 12% and 6% of total revenue was attributable to customers associated with the U.S. government, the UK government and the Australian government, respectively. During 2025, UK government contracts collectively represented approximately 39% of revenue for the year ended December 31, 2024 expired, representing a $5.0 million decrease in revenue for the year ended December 31, 2025. Based on results through December 31, 2025, management believes the expiration of these contracts did not have a material adverse impact on operating results, as increased revenue from U.S. and Australian government contracts during 2025 partially offset the reduction associated with the expired UK contracts by approximately $2.4 million.

Our government contracts typically involve defined phases or fixed terms, and it is common for individual contracts to expire as programs conclude or transition to new phases or follow-on arrangements. Accordingly, our ability to grow revenue in future periods will depend, in part, on our success in securing new government contracts and follow-on awards to replace or expand upon expiring programs.

***Partnership Opportunities***

Our future growth depends in part on our ability to successfully identify and enter into strategic partnership opportunities. We have historically entered into partnerships with major technology companies and academic organizations to enhance our capabilities, improve operational efficiencies, increase supply chain resilience and expand our addressable market. We expect we will continue to explore and enter new academic and commercial partnership opportunities that we believe are complementary to our business.

**Components of Results of Operations** 

***Revenue***

Our revenue is primarily derived from governmental contracts with the U.S. and allied government agencies and commercial contracts with research institutes and private companies primarily in the United States and Europe.

------

*Product revenue* 

Product revenue from governmental contracts is primarily derived from development projects resulting in product prototypes or projects to custom engineer a completed product to the customer's specifications. Product revenue from commercial contracts is derived from the sale of products to commercial customers, primarily from selling Tikqer for position navigation and timing ("PNT") use cases. Revenues under governmental contracts are generally recognized over time as we satisfy our performance obligations based on the extent of progress towards contract completion and product revenue under commercial contracts is generally recognized at a point in time when we satisfy our performance obligations and control of the product transfers to the customer.

*Service revenue* 

Service revenue is derived primarily from governmental contract revenue for research-related projects and commercial service revenue.

*Other revenue* 

Other revenue is comprised primarily of other award revenue.

***Cost of revenue***

*Cost of products* 

Cost of products primarily consists of labor, including direct labor and third-party specialist subcontractors, materials and equipment costs related to delivering our products, warranty expenses and an allocation of information technology costs, occupancy costs, and depreciation and amortization expense. Cost of products is recorded when the control of products is transferred to the customer.

*Cost of services* 

Cost of services primarily consists of labor, materials and equipment costs related to delivering our services, and an allocation of information technology costs, occupancy costs, and depreciation and amortization expense. Cost of services is recorded as services are performed.

***Research and development***

Research and development expenses primarily consist of personnel-related costs, including salaries, benefits and stock-based compensation, costs of materials, costs of consultants and allocated facility costs associated with the research, engineering, design and development of our quantum computing technologies.

***Selling, general and administrative***

Selling, general and administrative expenses primarily consist of personnel-related costs, including salaries, benefits and stock-based compensation, for employees performing bid, proposal, marketing and sales functions, for executive leadership and employees in legal, finance, accounting, and human resources, changes in contingent consideration, information technology and other administrative functions as well as allocated facility and consulting costs.

***Impairment of assets and goodwill***

Impairment of assets and goodwill includes impairment charges to write down goodwill, intangible assets and other long-lived assets primarily associated with previous acquisitions.

***Grant income***

Grant income includes income recognized from government grants, that are not accounted for as revenue from contracts with customers under ASC 606.

***Interest income***

Interest income consists primarily of interest earned on interest-bearing cash deposits and short-term, highly liquid investments.

***Change in fair value of SAFE liabilities***

Change in fair value of SAFE liabilities includes the fair value movement of our SAFE liabilities up to and including the date of settlement.

------

***Change in fair value of contingent consideration***

Changes in fair value of contingent consideration results from changes in the likelihood of the contingency becoming more or less probable over time.

***Other, net***

Other, net consists primarily of income from refundable research and development tax credits, interest expense related to borrowings and gains or losses resulting from fluctuations in exchange rates during the reporting period on unsettled transactions and outstanding balances with foreign subsidiaries, vendors or customers. Our exposure to foreign currency risk reflects our international operations and contracts, which are subject to changes in currency values.

***Income tax expense***

Income tax (benefit) expense consists of income taxes related to federal, state and foreign jurisdictions in which we conduct business.

**Results of Operations** 

***Comparison of the years ended December 31, 2025 and 2024***

The following table sets forth our statements of operations for the periods indicated (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** |
|  | **2025** | **2024** | **$ Change** | **% Change** |
|  **Revenue** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Product revenue | $19614 | $22325 | $(2711) | -12% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Service revenue | 12850 | 6511 | 6339 | 97% |
|  **Total revenue** | $**32464** | $**28836** | $**3628** | **13%** |
|  **Cost of revenue** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cost of products | 13558 | 17571 | (4013) | -23% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cost of services | 7093 | 2201 | 4892 | 222% |
|  **Total cost of revenue** | $**20651** | $**19772** | $**879** | **4%** |
|  **Gross profit** | **11813** | **9064** | **2749** | **30%** |
|  Research and development | 24089 | 22303 | 1786 | 8% |
|  Selling, general and administrative | 25343 | 27287 | (1944) | -7% |
|  Impairment of assets and goodwill |  | 13539 | (13539) | -100% |
|  Grant income | (2333) | (1057) | (1276) | 121% |
|  **Loss from operations** | $**(35286)** | $**(53008)** | $**17722** | **-33%** |
|  Other income (expense) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest income | 2502 | 1154 | 1348 | 117% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in fair value of SAFE liabilities |  | (2271) | 2271 | -100% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in fair value of contingent consideration |  | 380 | (380) | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other, net | 989 | (21) | 1010 | \* |
|  **Total other income (loss), net** | $**3491** | $**(758)** | $**4249** | \* |
|  **Loss before income taxes** | **(31795)** | **(53766)** | **21971** | **-41%** |
|  Income tax expense (benefit) |  | (2) | 2 | -100% |
|  **Net loss** | $**(31795)** | $**(53764)** | $**21969** | **-41%** |

---

*\** *Not meaningful* 

*Total revenue* 

Total revenue increased by $3.6 million, or 13%, to $32.5 million for the year ended December 31, 2025, compared to $28.8 million for the year ended December 31, 2024. The increase was primarily driven by an increase of $6.3 million in service revenue that was partially offset by a decrease of $2.7 million in product revenue.

------

The increase in service revenue was primarily driven by a $6.2 million increase related to services performed under the QGG contract with NASA and a $0.3 million increase related to the European Space Agency and National Security Strategic Fund projects. These increases were partially offset by a $0.2 million decrease in service revenue across other projects.

The decrease in product revenue was primarily driven by a decline in revenue related to projects that were completed in 2024 or early part of 2025, including a $6.8 million decrease associated with the expiration of contracts with the UK government and a $3.5 million decrease related to the final phase and completion of the Quantum Moonshot program with the Japan Science and Technology Association. Revenue was further offset by a $2.1 million decrease related to other contracts, including with NASA, the U.S. Department of Defense and the Naval Research Laboratory. These decreases were partially offset by new contracts entered into in late 2024 and early 2025, including $6.2 million related to the U.S. Department of Defense. In addition, product revenue from ongoing contracts increased by $1.0 million and $0.8 million related to the European Space Agency and Innovate UK projects in the UK, respectively, and by $1.8 million from contracts with the Australian government.

*Total cost of revenue* 

Total cost of revenue increased by $0.9 million, or 4%, to $20.7 million for the year ended December 31, 2025, compared to $19.8 million for the year ended December 31, 2024. The increase was primarily driven by a $4.9 million increase in cost of services, reflecting a $2.1 million increase in subcontractor costs, a $1.8 million increase in labor costs and a $0.8 million increase in overhead allocations. These increases were partially offset by a $4.0 million decrease in cost of products, primarily due to a $4.4 million decrease in materials, partially offset by $0.4 million of consultant costs.

*Research and development* 

Research and development expense increased by $1.8 million, or 8%, to $24.1 million for the year ended December 31, 2025, compared to $22.3 million for the year ended December 31, 2024. The increase was primarily driven by a $0.9 million increase in depreciation expense related to a quantum computer placed into service in October 2024, a $0.5 million increase in payroll and other compensation costs due to higher bonuses and a $0.3 million increase in lab materials and expenses.

*Selling, general and administrative* 

Selling, general and administrative expense decreased by $1.9 million, or 7%, to $25.3 million for the year ended December 31, 2025, compared to $27.3 million for the year ended December 31, 2024, primarily driven by a $7.7 million reduction in payroll and other compensation costs attributable to workforce reductions implemented in 2024, $0.8 million decrease in share-based compensation expense as no options were granted for the second half of 2025, a $0.7 million decrease in marketing related expenses, as well as a $0.2 million decrease in travel related expenses. These decreases were partially offset by a $4.1 million expense related to changes in the fair value of a contingent obligation and a $3.7 million increase in accounting fees.

*Impairment of assets and goodwill* 

Impairment of assets and goodwill totaled $13.5 million for the year ended December 31, 2024, consisting of $11.6 million of intangible asset impairments related to the Morton Acquisition and the SiNoptiq asset acquisition, a $1.5 million goodwill impairment related to the Morton Acquisition, and a $0.3 million impairment of an operating lease right-of-use asset. There were no impairment charges recorded during the year ended December 31, 2025.

*Grant income* 

Grant income increased by $1.2 million, or 121%, to $2.3 million for the year ended December 31, 2025, compared to $1.1 million for the year ended December 31, 2024. The increase was primarily driven by grant funding received from U.S. and UK governmental agencies in early 2025, including $0.5 million related to grants in the UK and $0.3 million related to grants in the U.S. This increase was partially offset by a $0.3 million decrease across eight grants during 2025.

------

*Other income (expense)* 

*Interest income, net* 

Interest income increased by $1.3 million, or 117%, to $2.5 million for the year ended December 31, 2025, compared to $1.2 million for the year ended December 31, 2024. The increase was primarily driven by higher average invested balances in government money market funds and marketable securities, funded with proceeds from issuances of Series C redeemable preferred stock in December 2024 and the first half of 2025.

*Change in fair value of SAFE liabilities* 

The change in fair value of SAFE liabilities totaled $2.3 million for the year ended December 31, 2024, related to SAFE notes issued between December 2023 and May 2024. No fair value adjustments were recorded during the year ended December 31, 2025, as the SAFE notes were converted into 22,869,771 shares (prior to the application of the Exchange Ratio) of Series C redeemable preferred stock in December 2024.

*Other, net* 

Other income, net increased by $1.0 million for the year ended December 31, 2025, compared to a loss of $21.0 thousand for the year ended December 31, 2024, primarily due to income recognized from UK research and development tax credit refunds.

**Liquidity and Capital Resources** 

We have incurred net losses and used cash in operating activities since inception. Historically, we have funded our operations primarily through the issuance of convertible redeemable preferred stock and have raised aggregate gross proceeds of approximately $285.4 million. For the year ended December 31, 2025, we incurred a net loss of $31.8 million, and as of December 31, 2025, we had an accumulated deficit of $231.1 million. We expect to continue to incur operating losses and higher operating expenses for the foreseeable future as we invest in the development and commercialization of our technologies.

Our cash and cash equivalents consist primarily of cash held in banks, checking deposits and money market funds. As of December 31, 2025, we had cash and cash equivalents, including restricted cash of $11.9 million. At the Closing of the Business Combination, our cash position increased significantly as a result of proceeds received from the PIPE Investment of approximately $126.5 million and proceeds of approximately $424.8 million from funds held in CCX's trust account, partially offset by approximately $35.8 million of transaction-related costs.

Based on our current operating plan, management believes that our cash and cash equivalents on hand as of December 31, 2025 and the proceeds received at the Closing of the Business Combination will be sufficient to meet our anticipated working capital and capital expenditure requirements for at least 12 to 18 months from the date of this Current Report on Form 8-K/A. This assessment is based on internal projections and assumptions and is subject to changes in market conditions, business execution and other factors.

Our future capital requirements will depend on a number of factors, including our ability to attract and retain customers and employees, the market acceptance of our products and services, the timing and scope of customer contracts, the development and launch of new or enhanced products, expansion of sales and marketing activities, and general economic conditions. Our primary short-term cash requirements include funding working capital needs and operating lease obligations. Working capital requirements may fluctuate significantly from period to period, particularly due to the timing of receipts and payments associated with long-term customer contracts. Our medium-to long-term cash requirements are expected to consist primarily of investments in facilities, equipment, personnel, research and development activities, and potential strategic acquisitions.

We may elect, or be required, to seek additional capital through public or private equity financings, debt financings or other sources. However, additional financing may not be available on acceptable terms, or at all.

Our product roadmap benefits significantly from external funding sources to advance the technological roadmap across quantum sensing and quantum computing as technological advances in these areas are funded as cost of sales of the respective programs rather than through internal research and development. In addition, we invest aggressively in research and development across quantum sensing and quantum computing, including capital expenditures, business development and engineering. In addition to the quantum computers in our technological roadmap, we also develop full-stack quantum computers and quantum computing test-beds to push the technological frontier of these programs, enabling advances in quantum computing architecture, integrated photonics and vacuum cell technologies, as well as improvements in gate fidelity and quantum error correction. We expect to continue to invest in research and development as a public company to fund these technological priorities and realize our goal of at-scale, fault-tolerant quantum computing.

------

In addition to our research and development efforts, we have historically invested in demonstration units that can be deployed in the field and showcased to customers in a variety of real-world, in-situ environments, such as Tiqker clocks for long-term testing and quantum radio frequency systems that can be used to demonstrate an array of use cases to a variety of potential end-customers. We have also historically pursued acquisitions to expand our capabilities, de-risk our technological roadmaps and readily scale resources. We expect that we will continue to make investments in strategic acquisition opportunities going forward.

***Convertible Redeemable Preferred Stock***

The following table sets out our convertible redeemable preferred stock issued and outstanding as of December 31, 2025 (in thousands, except share data), which is presented prior to the application of the Exchange Ratio:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** |
|  | **Shares<br>Authorized** | **Shares** <br>**Issued and<br>Outstanding** | **Carrying<br>Value** | **Aggregate<br>Liquidation<br>Preference** |
|  Series Seed | 24871033 | 24871033 | $6526 | $6750 |
|  Series Seed II | 27499984 | 27499984 | 10411 | 10450 |
|  Series A | 101515976 | 101515976 | 36658 | 36830 |
|  Series B | 113956319 | 113956319 | 112145 | 115962 |
|  Series B-1 | 32419574 | 32419574 | 32990 | 20813 |
|  Series C | 60777953 | 60399952 | 71733 | 74534 |
|  Series C-1 | 22869771 | 22869771 | 26351 | 23988 |
|  **Total Convertible Preferred Stock** | **383910610** | **383532609** | $**296814** | $**289327** |

---

------

*Series Seed, Series Seed II and Series A Convertible Redeemable Preferred Stock* 

The holders of our Series Seed, Series Seed II and Series A convertible redeemable preferred stock are entitled to receive non-cumulative cash dividends on a pari passu basis, in preference to holders of our common stock at a rate of 6% of the original issue price of the applicable series per year if and when declared by the Infleqtion Board. Each share of the Series Seed, Series Seed II and Series A convertible redeemable preferred stock is convertible into one share of our common stock (prior to the application of the Exchange Ratio), subject to adjustment for certain dilutive issuances, at the option of the holder at any time for no additional consideration and is mandatorily convertible upon the occurrence of certain events.

*Series B, Series B-1, Series C and Series C-1 Preferred Stock* 

The holders of our Series B, Series B-1, Series C and Series C-1 convertible redeemable preferred stock are entitled to receive non-cumulative cash dividends in preference to holders of our Series Seed, Series Seed II and Series A convertible redeemable preferred stock and common stock at a rate of 6% of the original issue price of each series per year only if and when declared by the Infleqtion Board. Each share of the Series B, Series B-1, Series C and Series C-1 convertible redeemable preferred stock is convertible into one share of our common stock (prior to the application of the Exchange Ratio) at the option of the holder at any time for no additional consideration and is mandatorily convertible upon the occurrence of certain events.

Refer to Note 13 to our consolidated financial statements included elsewhere in this Current Report on Form 8-K/A for additional information about our convertible redeemable preferred stock.

***Cash Flows***

The following table summarizes our cash flows and cash and cash equivalents, for the years ended December 31, 2025 and 2024 (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Years ended December 31,** | **Years ended December 31,** |
|  | **2025** | **2024** |
|  Net cash used in operating activities | $(24145) | $(32467) |
|  Net cash provided by (used in) investing activities | (53531) | 4106 |
|  Net cash provided by financing activities | 40752 | 48390 |
|  Foreign currency translation | 676 | 451 |
|  Net (decrease) increase in cash and cash equivalents and restricted cash | (36248) | 20480 |
|  Cash and cash equivalents and restricted cash at beginning of period | 48142 | 27662 |
|  Cash and cash equivalents and restricted cash at end of period | $11894 | $48142 |

---

------

*Cash used in operating activities* 

Net cash used in operating activities was $24.1 million for the year ended December 31, 2025, compared to $32.5 million for the year ended December 31, 2024, representing an $8.4 million decrease in cash used. This change was primarily attributable to a $22.0 million decrease in net loss, partially offset by a $12.3 million decrease in non-cash adjustments and $1.3 million increase in cash used by working capital changes.

Non-cash adjustments decreased by $12.3 million in 2025 compared to 2024, primarily due to $13.5 million of impairment charges recognized in 2024 related to the Morton Acquisition and the SiNoptiq asset acquisition, with no comparable impairment charges in 2025. Non-cash adjustments also decreased due to (i) a $2.3 million change in fair value of SAFE liabilities recorded in 2024 with no corresponding adjustment in 2025, (ii) a $0.7 million decrease in stock-based compensation, (iii) a $0.7 million non-cash transfer of property and equipment, and (iv) other non-cash adjustments of $0.6 million, primarily attributable to an unrealized foreign currency remeasurement (gain) loss and net amortization of premiums and accretion of discounts on available-for-sale securities, and interest accretion on deferred cash consideration. These decreases were partially offset by (i) a $4.0 million change in fair value of contingent obligation recognized in 2025 related to the Morton amendment, with no comparable charges in 2024 and increases in (ii) depreciation and amortization of $1.1 million and (iii) change in fair value of a contingent obligation of $4.0 million.

Net cash impact from changes in working capital increased by $1.3 million in 2025 compared to 2024. The change was primarily driven by decreases in (i) operating right-of-use liabilities of $3.6 million due to the normal course of business, (ii) accrued liabilities of $4.1 million primarily driven by payment of capitalized costs, (iii) accounts receivable of $3.4 million primarily related to the conclusion of contracts with the U.K. government, (iv) inventories of $1.1 million, and (v) other current assets of $0.8 million. This was offset by an increase in: (i) accounts payable of $4.8 million primarily driven by higher accrued audit, legal and other professional fees incurred in preparation of the Business Combination, higher operating expenditures associated with scaling the Company's operations, and the timing of vendor payments at year-end, (ii) operating lease right-of-use assets of $3.2 million due to the normal course of business, (iii) contract liabilities of $2.6 million due to the timing of revenue recognition, customer billings, and advance payments associated with the increased revenue activity during the year, and (iv) unbilled receivables of $1.1 million.

*Cash provided by (used in) investing activities* 

Net cash used in investing activities was $53.5 million for the year ended December 31, 2025, compared to net cash provided by investing activities of $4.1 million for the year ended December 31, 2024. The $57.6 million change was primarily driven by $56.8 million of available-for-sale securities purchases during 2025 and a $7.1 million decrease in available-for-sale securities redemptions, partially offset by (i) a $5.7 million decrease in net cash paid for acquisitions reflecting the absence of acquisition activity in 2025 and (ii) a $0.5 million decrease in purchases of property and equipment.

*Cash provided by financing activities* 

Net cash provided by financing activities was $40.8 million for the year ended December 31, 2025, compared to $48.4 million for the year ended December 31, 2024, representing a $7.6 million decrease. The change was primarily driven by (i) $22.7 million of lower proceeds from the issuance of SAFE notes, net of issuance costs, (ii) higher cash outflows related to offering costs of $5.2 million and accrued issuance costs of $2.8 million, (iii) $1.0 million of deferred cash consideration, and (iv) $0.1 million of lower proceeds from stock option exercises. These decreases were partially offset by an increase of $24.1 million in proceeds from the issuance of Series C convertible redeemable preferred stock.

***Contractual Obligations and Commitments***

The commitment amounts presented below are associated with material contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts.

*Operating lease obligations* 

We utilize non-cancellable operating leases for various real estate in Colorado, Wisconsin, the U.K. and Australia primarily used as office space, which expire at various dates through 2030 and some of which contain multi-year renewal options. As of December 31, 2025, our remaining contractual obligations for our operating lease obligations were approximately $5.2 million. See Note 17 to our consolidated financial statements included elsewhere in this Current Report on Form 8-K regarding the timing of expected future payments and for additional information.

------

*Contingent payments* 

In May 2025, the Company amended the equity purchase agreement related to the Morton Acquisition. The amendment added new milestones that, if achieved, requires the Company to make the remaining contingent cash payments of approximately $0.2 million and results in the vesting of the remaining 1,639,145 outstanding shares (prior to the application of the Exchange Ratio) of restricted common stock. Additional information regarding the original purchase agreement and related contingent consideration is provided in Note 3 to our consolidated financial statements included elsewhere in this Current Report on Form 8-K.

The contingent obligation is classified as a liability and is remeasured at fair value each reporting period, with changes in fair value recognized in earnings. Refer to Note 1 to our consolidated financial statements included elsewhere in this Current Report on Form 8-K for information regarding the valuation methodology and significant unobservable inputs used in measuring the contingent obligation. At the date of the amendment, the Company assessed the likelihood that the milestones related to the contingent payments would be met and recognized a contingent obligation measured at fair value, with a corresponding expense recorded in selling, general and administrative expenses in the consolidated statement of operations and comprehensive loss. Subsequent to the amendment, certain milestones were achieved, and the Company settled $2.3 million of the contingent obligation, consisting of $0.1 million in cash payments and the vesting of 948,979 shares (prior to the application of the Exchange Ratio) of restricted common stock with an estimated fair value of $2.2 million. During the year ended December 31, 2025, a total of $4.1 million of expense was recorded within selling, general and administrative expenses related to the remeasurement of the contingent obligation. The remaining balance of the contingent obligation included in accrued liabilities on the consolidated balance sheet was $1.8 million as of December 31, 2025.

The SiNoptiq asset acquisition provides for contingent payments for sales-and development-based milestones of up to $1.5 million in cash and 1,474,056 restricted shares (prior to the application of the Exchange Ratio) of Series B convertible redeemable preferred stock. The rights to these contingent payments expire on January 26, 2028. At the acquisition date, we assessed the likelihood of the contingencies to be met as not probable and do not expect this assessment to change.

See Note 12 to our consolidated financial statements included elsewhere in this Current Report on Form 8-K for additional information on our contingent payments.

*Deferred consideration payable* 

In addition to contingent consideration, as of December 31, 2025, we also owed deferred cash consideration of $0.5 million related to the SiNoptiq asset acquisition.

Refer to Note 12 to our consolidated financial statements included elsewhere in this Current Report on Form 8-K/A for additional information on our contractual obligations and commitments.

**Off-Balance Sheet Arrangements** 

We did not have any material off-balance sheet arrangements during the periods presented, and do not currently have any material off-balance sheet financing arrangements or any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities, that were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

**Critical Accounting Policies and Estimates** 

Our consolidated financial statements included in this Current Report on Form 8-K/A have been prepared in accordance with GAAP. Preparation of the financial statements requires our management to make judgments, estimates and assumptions that impact the reported amounts of net sales and expenses, assets and liabilities and the disclosure of contingent assets and liabilities. We consider an accounting judgment, estimate or assumption to be critical when the estimate or assumption is complex in nature or requires a high degree of judgment and the use of different judgments, estimates and assumptions could have a material impact on our consolidated financial statements. Management periodically reviews the Company's estimates and adjusts those estimates when facts and circumstances dictate. To the extent that there are material differences between these estimates and actual results, its financial condition or results of operations will be affected.

------

While our significant accounting policies are described in Note 1 to our audited consolidated financial statements included elsewhere in this Current Report on Form 8-K/A, we believe the following critical accounting policies are most important to understanding and evaluating our reported financial results.

**Revenue Recognition** 

We recognize revenue primarily from governmental and commercial contracts, applying judgment in determining the timing and pattern of revenue recognition based on contract terms and performance obligations. Governmental revenues, typically tied to research and product development contracts with single performance obligations, are recognized over time using cost input methods reflecting continuous transfer of control. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. We generally use the cost input measures of progress for our contracts because it best depicts the transfer of control to the customer which occurs as we incur costs on our contracts. Commercial revenues, mostly related to distinct product sales, are recognized at a point in time upon transfer of control, usually at shipment.

In accounting for contracts, we rely on estimates, including variable consideration and contract estimates, to project the outcome of future events that may span multiple years. These assumptions include but are not limited to: the time required to complete the contract; the assessment of the work we are contractually required to perform; the cost and availability of labor and materials; and the funding from the customer. For fixed-price contracts, we bear the risk of changes in estimates to complete which may cause various profit metrics to vary period-to-period.

Accounting for contracts recognized over multiple periods requires significant judgment, in particular, our estimates on the time to complete including the assessment of the nature and complexity of the work we will perform. Our estimates are based on the professional knowledge and experience of our engineers, program managers, management, and other relevant personnel who review our over-time contracts monthly to reassess the contract's current estimated cost, technical matters, to-date performance, remaining performance, and remaining schedule through to completion.

**Intangible Assets and Goodwill** 

Intangible assets acquired in a Business Combination that qualify for separate recognition are recognized as intangible assets at their fair value and amortized on a straight-line basis over their estimated useful lives. When facts and circumstances indicate that the carrying value of definite-lived intangible assets may not be recoverable, management assesses the recoverability of the carrying value by preparing estimates of sales volume and the resulting profit and cash flows expected to result from the use of the asset or asset group and its eventual disposition. If the fair value is less than the carrying amount, we recognize an impairment loss.

Goodwill is measured as the excess of the purchase price over the fair value of the assets acquired and liabilities assumed in a Business Combination. We test goodwill for impairment on an annual basis, which is determined to be the first day of the fourth quarter, and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. In order to test for goodwill impairment, we may elect to perform a qualitative assessment of goodwill in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount which would require a quantitative test. If we perform a quantitative test, we compare the fair value of the reporting unit to carrying value, including goodwill. In estimating the fair value of our reporting unit, our approach may incorporate observable market data, including comparable company trading multiples, recent market transactions, cash flow projects, discount rates and other relevant valuation metrics. If the fair value of the reporting unit is lower than its carrying amount, an impairment of goodwill is recognized for the amount by which the carrying amount exceeds the fair value.

For the year ended December 31, 2025, there were no goodwill or intangible asset impairments recorded. For the year ended December 31, 2024, we have recorded goodwill impairment of $1.5 million and intangible asset impairments of $11.6 million.

**Convertible Redeemable Preferred Stock** 

As all series of our preferred stock are contingently redeemable upon the occurrence of events not solely within our control, the preferred stock is presented as mezzanine equity, separate from the stockholders' deficit section of the consolidated balance sheet. The preferred stock is initially recorded at the fair value determined on the issuance date. Adjustments to the fair value of the preferred stock to the current market value are not made each period. Rather, we assess whether the convertible preferred stock has become redeemable or the probability that the preferred stock will become redeemable in determining whether to record subsequent measurement adjustments.

------

The Company's Series A, B, B-1, Seed II, Seed, C and C-1 Preferred Stock are not currently redeemable or probable of becoming redeemable in the future period. As of the closing of the Business Combination, all preferred stock was surrendered and exchanged for the right to receive CCX common stock, representing shares of Infleqtion, Inc. common stock following the Closing. Refer to Note 13 to our audited consolidated financial statements included elsewhere in this Current Report on Form 8-K/A for additional information.

**Stock-Based Compensation** 

All of our share-based payment awards are equity-classified and consist of stock options and RSAs. Share-based compensation cost is measured based on the fair value of the awards as determined on the grant date. We recognize stock-based compensation expense using the graded attribution method in which expense is recognized on a straight-line basis over the requisite service period for each separately vesting portion of the stock option or RSA as if the award was, in substance, multiple awards.

The fair value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires extensive use of accounting judgment and financial estimates, including estimates of the fair value of the underlying common stock, the expected term participants will retain their vested stock options before exercising them, the estimated volatility of the common stock price over the expected term, the risk free rate, and expected dividend yield. The fair value of restricted stock awards is determined based on the estimated fair market value of our common stock on the grant date. Prior to the Closing, our shares were not publicly traded, the fair market value was established through an independent third-party valuation, which considered a number of factors, including recent equity transactions, financial performance, peer companies, and other relevant qualitative and quantitative inputs. We account for forfeitures as they occur.

**Recently Issued or Adopted Accounting Standards** 

A description of recently issued and adopted accounting pronouncements are described in Note 1 to our audited consolidated financial statements included elsewhere in this Current Report on Form 8-K/A.